




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 295/155, 295/135, A61K 31/445, 31/495, A61P 3/06, 9/10	A1	(11) International Publication Number: WO 00/32582 (43) International Publication Date: 8 June 2000 (08.06.00)
(21) International Application Number: PCT/EP99/09320 (22) International Filing Date: 1 December 1999 (01.12.99) (30) Priority Data: 9826412.0 3 December 1998 (03.12.98) GB (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): DAUGAN, Alain, Claude-Marie [FR/FR]; Laboratoire Glaxo Wellcome, Centre de Recherches, ZA de Courtaboeuf, 25, avenue de Québec, F-91940 Les Ulis (FR). (74) Agent: LEAROYD, Stephanie, Anne; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS

**(57) Abstract**

The invention relates to therapeutic benzamide compounds of formula (I) wherein A represents N or CH; X is selected from the following groups: (i) -C₁₋₆alkylene-, optionally containing one or two double bonds and optionally substituted by one or more hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ acyl or C₁₋₆ acyloxy groups, (ii) oxo, sulfonyl, thioxo, (iii) -C₁₋₆alkylenecarbonyl-, -C₁₋₆alkylenesulfonyl-, -C₁₋₆alkylenethioxo-, (iv) -C₂₋₆alkyleneoxy-, -C₂₋₆alkylenethio-, -C₂₋₆alkylene(N-H or N-C₁₋₆alkyl)amino-, (v) -C₁₋₆alkylenecarboxy-, -C₁₋₆alkylenethioamido-, -C₁₋₆alkylene(N-H or N-C₁₋₆alkyl)carboxamido-, and (vi) -C₂₋₆alkyleneoxycarbonyl-, -C₂₋₆alkylenethiocarbonyl-, -C₂₋₆alkylene(N-H or N-C₁₋₆alkyl)aminocarbonyl-; Z represents a direct link or -C₁₋₆alkylene-, optionally containing one double bond and optionally substituted by one or more hydroxy, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ acyl or C₁₋₆ acyloxy groups; R¹ is selected from the following groups: (i) hydrogen, C₁₋₃perfluoroalkyl, (ii) C₆₋₁₀ aryl, C₃₋₈cycloalkyl and fused benz derivatives thereof, C₇₋₁₀polycycloalkyl, C₄₋₈cycloalkenyl, C₇₋₁₀polycycloalkenyl, (iii) a heterocyclyl selected from the group consisting of monocyclic radicals and fused polycyclic radicals, and (iv) where either X is C₁₋₆alkylene and Z is a direct link, or Z is C₁₋₆alkylene; R¹ additionally may represent a halogen, cyano, nitro or C₁₋₆acyl group, wherein, when R¹ contains one or more rings, said rings may each independently bear 0 to 4 substituents. Y represents a direct or oxy link, -C₁₋₆alkylene-, -oxyC₁₋₆alkylene- or a heterocyclyl consisting of monocyclic radicals. R² represents phenyl, C₃₋₈cycloalkyl, or a heterocyclyl consisting of monocyclic radicals, and where each R² is optionally substituted by one or more groups independently selected from halogen, C₁₋₄alkyl, C₁₋₄alkoxy, C₃₋₈cycloalkyl, C₁₋₃perfluoroalkyl, C₁₋₄perfluoroalkoxy, hydroxycarbonyl, C₁₋₆alkoxycarbonyl, cyano, nitro, C₁₋₄alkylaminosulfonyl; R³ represents hydrogen or one or more groups independently selected from halogen, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₃perfluoroalkyl or C₁₋₃perfluoroalkoxy; or a physiologically acceptable salt, solvate or derivative thereof, pharmaceutical compositions, to processes for their preparation and their use in the treatment of conditions mediated by ApoB-100 regulation.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		


BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS

This invention relates to novel compounds which inhibit hepatic production of apoprotein B-100 (apoB-100), and to processes for their preparation, pharmaceutical compositions containing them and their medical use.

ApoB-100 is the main protein component of low density lipoprotein-cholesterol (LDL-C). High LDL-C plasmatic levels are a major risk factor for atherosclerosis and coronary artery diseases. ApoB-100 plasmatic levels correlate with LDL-C plasmatic levels and also constitute a cardiovascular risk factor in themselves. ApoB-100 is exclusively produced by hepatocytes and reducing hepatic production of ApoB-100 should induce a decrease of LDL-C plasmatic levels.

Compounds having ApoB-100 inhibition properties have been described in WO96/40640, which is incorporated herein by reference.

The present invention provides a compound of formula (I)



wherein

A represents N or CH;

X is selected from the following groups:

- (i) $-C_{1-6}$ alkylene-, optionally containing one or two double bonds and optionally substituted by one or more hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} acyl or C_{1-6} acyloxy groups,
- (ii) oxo, sulfonyl, thioxo,
- (iii) $-C_{1-6}$ alkylenecarbonyl-, $-C_{1-6}$ alkylenesulfonyl-, $-C_{1-6}$ alkylenethioxo-,

- (iv) $-C_{2-6}$ alkyleneoxy-, $-C_{2-6}$ alkylenethio-, $-C_{2-6}$ alkylene(N-H or N- C_{1-6} alkyl)amino-,
 (v) $-C_{1-6}$ alkylenecarboxy-, $-C_{1-6}$ alkylenethioamido-, $-C_{1-6}$ alkylene(N-H or N- C_{1-6} alkyl)carboxamido-, and
 5 (vi) $-C_{2-6}$ alkyleneoxycarbonyl-, $-C_{2-6}$ alkylenethiocarbonyl-, $-C_{2-6}$ alkylene(N-H or N- C_{1-6} alkyl)aminocarbonyl-;

10 Z represents a direct link or $-C_{1-6}$ alkylene-, optionally containing one double bond and optionally substituted by one or more hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} acyl or C_{1-6} acyloxy groups;

R^1 is selected from the following groups:

- (i) hydrogen, C_{1-3} perfluoroalkyl,
 15 (ii) C_{6-10} aryl, C_{3-8} cycloalkyl and fused benz derivatives thereof,
 C_{7-10} polycycloalkyl, C_{4-8} cycloalkenyl, C_{7-10} polycycloalkenyl,
 (iii) a heterocyclyl selected from the group consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of from 5-14 ring atoms, wherein said radicals contain a total of from 1-4 ring heteroatoms independently selected from oxygen,
 20 nitrogen and sulfur, and wherein individual rings of said radicals may be independently saturated, partially unsaturated, or aromatic, and
 (iv) where either X is C_{1-6} alkylene and Z is a direct link, or Z is C_{1-6} alkylene, R^1 additionally may represent a halogen, cyano, nitro or C_{1-6} acyl group,

25 wherein, when R^1 contains one or more rings, said rings may each independently bear 0 to 4 substituents independently selected from

- (i) halogen, hydroxy, cyano, nitro, formyl, C_{1-6} alkylsulfonylamino,
 (ii) C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-3} perfluoroalkyl,
 30 (iii) C_{1-6} alkoxy, methylenedioxy, C_{1-3} perfluoroalkoxy, C_{1-6} alkylthio,
 (iv) amino, C_{1-6} alkylamino, di- C_{1-6} alkylamino,
 (v) phenyl, phenoxy, phenylthio, halophenylthio, benzyl, benzyloxy;
 (vi) hydroxycarbonyl, C_{1-6} alkoxycarbonyl,
 35 (vii) aminocarbonyl, C_{1-6} alkylaminocarbonyl, di- C_{1-6} alkylaminocarbonyl, di- C_{1-6} alkylaminocarbonyl/ C_{1-6} alkoxy, C_{1-3} perfluoroalkylaminocarbonyl,

- (viii) C_{1-6} acyl, C_{1-6} acyloxy, C_{1-6} acyloxy C_{1-6} alkyl, C_{1-6} acylamino, and
(ix) an aromatic heterocyclyl consisting of monocyclic radicals, wherein said radicals contain 5-6 ring atoms, wherein said radicals contain a total of from 1-4 ring heteroatoms independently selected from oxygen, nitrogen and sulfur, and where each of the said heterocyclyl groups is optionally substituted by one or more groups independently selected from halogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-3} perfluoroalkyl and C_{1-3} perfluoroalkoxy;

Y represents a direct or oxy link, $-C_{1-6}$ alkylene-, $-oxyC_{1-6}$ alkylene- or a heterocyclyl consisting of monocyclic radicals, wherein said radicals contain 5 ring atoms, and wherein said radicals contain a total of from 1-4 ring heteroatoms independently selected from oxygen, nitrogen and sulfur and wherein the ring may be independently saturated, partially unsaturated, or aromatic;

R^2 represents phenyl, C_{3-8} cycloalkyl, or a heterocyclyl consisting of monocyclic radicals, wherein said radicals contain a total of from 5-6 ring atoms, wherein said radicals contain a total of from 1-4 ring heteroatoms independently selected from oxygen, nitrogen and sulfur, wherein the ring may be independently saturated, partially unsaturated, or aromatic, and where each R^2 is optionally substituted by one or more groups independently selected from halogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{3-8} cycloalkyl, C_{1-3} perfluoroalkyl, C_{1-3} perfluoroalkoxy, hydroxycarbonyl, C_{1-6} alkoxycarbonyl, cyano, nitro, C_{1-4} alkylaminosulfonyl;

R^3 represents hydrogen or one or more groups independently selected from halogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-3} perfluoroalkyl or C_{1-3} perfluoroalkoxy; or a physiologically acceptable salt, solvate or derivative thereof.

Suitable physiologically acceptable salts of the compounds of general formula (I) include acid addition salts formed with pharmaceutically acceptable organic and inorganic acids for example, citrates, hydrochlorides, hydrobromides, or sulphates. Particularly preferred salts are citrates or hydrochloride salts.

The solvates may, for example, be hydrates.

References hereinafter to a compound according to the invention include both compounds of formula (I) and their physiologically acceptable salts together with physiologically acceptable solvates.

5 Referring to the general formula (I), alkyl, alkylene and alkoxy include both straight and branched chain saturated hydrocarbon groups. Examples of alkyl groups include methyl and ethyl groups, examples of alkylene groups include methylene and ethylene groups, whilst examples of alkoxy groups include methoxy and ethoxy groups.

10

Referring to general formula (I), a halogen atom may be a fluorine, chlorine, bromine or iodine atom.

15

Referring to the general formula (I), reference to heterocyclyl, unless otherwise defined, means any single ring or fused ring system containing at least one ring heteroatom independently selected from O, N and S. Thus, a polycyclic fused ring system containing one or more carbocyclic fused saturated, partially unsaturated, or aromatic rings (usually benz rings) is within the definition of heterocyclyl so long as the system also contains at least one fused ring which contains at least one of the aforementioned heteroatoms. As a substituent, such heterocyclyls may be attached to the remainder of the molecules from either a carbocyclic (e.g. benz) ring or from a heterocyclic ring.

20

25 Referring to the general formula (I), reference to R¹ as containing one or more rings is intended to mean any single or fused cyclic moiety or moieties attached to Z. The rings may be carbocyclic or heterocyclic, saturated or partially unsaturated, and aromatic or non-aromatic.

25

30 Reference to a polycyclic ring system or radical means that all rings in the system are fused.

30

Referring to the general formula (I), aryl means that the ring or substituent is carbocyclic and includes phenyl and naphthyl.

Referring to the general formula (I), acyl refers to aliphatic or cyclic hydrocarbons attached to a carbonyl group through which the substituent bonds.

Referring to the general formula (I), methylenedioxy refers to a $x,x+1$ -methylenedioxy group, where x and $x+1$ are integers which represent the substitution pattern on the ring, e.g. 3,4-methylenedioxy.

Referring to the general formula (I), $C_{1,3}$ perfluoroalkyl or $C_{1,3}$ perfluoroalkoxy includes compounds such as trifluoromethyl and trifluoromethoxy.

Suitably, the piperazine or piperidine group in formula (I) is substituted meta or para, most suitably para substituted. Preferably, A represents N.

X is suitably $-C_{1,6}$ alkylene-, optionally containing by one double bond, e.g. methylene, ethylene, propylene or but-2-enylene, oxo, sulfonyl, $-C_{2,6}$ alkyleneoxy-, e.g. ethyleneoxy or propyleneoxy, $-C_{1,6}$ alkylenecarboxy-, e.g. methylenecarboxy or $-C_{1,6}$ alkylene(N-H or N- $C_{1,6}$ alkyl)carboxamido-, e.g. methylene(N-H)carboxamido.

~~X is equally suitably methylene, oxo, or sulfonyl. As a preferred aspect, X is a methylene group.~~

Z is suitably a direct link or $C_{1,6}$ alkylene, e.g. methylene or ethylene. Z is most suitably a direct link.

R^1 is suitably selected from the following groups

- (i) hydrogen, cyano, $C_{1,3}$ perfluoroalkyl, e.g. trifluoromethyl,
- (ii) optionally substituted phenyl, where optional substitution is effected by one or two groups independently selected from $C_{1,6}$ alkyl, e.g. methyl, cyano, halogen, e.g. fluoro, $C_{1,6}$ alkoxy, e.g. methoxy, $C_{1,3}$ perfluoroalkyl, e.g. trifluoromethyl, hydroxycarbonyl, $C_{1,4}$ alkoxycarbonyl, e.g. methoxycarbonyl, aminocarbonyl, methylenedioxy, nitro, $C_{1,6}$ acyl, e.g. acetyl, phenyl, or an optionally substituted aromatic heterocycl consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of 5 ring atoms, e.g. oxadiazolyl, where

optional substitution is effected by C_{1-4} alkyl, e.g. methyl, or C_{1-3} perfluoroalkyl, e.g. trifluoromethyl, or

- (iii) an optionally substituted aromatic heterocyclyl consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of from 5-10 ring atoms, e.g. indolyl, pyrrolyl, thienyl, furanyl, imidazolyl, pyrazolyl, thiazolyl, pyridyl or pyrazinyl, where optional substitution is effected by C_{1-4} alkyl, e.g. methyl, or halogen, e.g. fluorine.

Where R^1 is a substituted phenyl group, substitution is suitably in the 3-position.

When R^1 is an optionally substituted aromatic heterocyclyl, R^1 is preferably an optionally substituted pyrrolyl, where optional substitution is effected by a methyl group. Most preferably, the substitution pattern is 2-pyrrolyl.

R^1 is more suitably selected from the following groups

- (i) hydrogen,
- (ii) substituted phenyl, where substitution is effected by cyano or a methyl substituted oxadiazolyl group, or
- (iii) a pyrrolyl group

X-Z is suitably methylene or oxo and R^1 is suitably phenyl or a heterocyclyl, e.g. pyrrolyl, furanyl, C-linked imidazolyl, thienyl, pyrazolyl, thiazolyl, triazolyl, indolyl, pyridyl, N-Me-imidazolyl or pyrazinyl, where each R^1 is optionally substituted by one or more groups independently selected from C_{1-6} alkyl, e.g. methyl, cyano, halogen, e.g. fluoro, C_{1-6} alkoxy, e.g. methoxy, trifluoromethyl, hydroxycarbonyl and C_{1-4} alkoxycarbonyl, e.g. methoxycarbonyl.

R^1 is preferably phenyl substituted by 3-cyano.

As a most preferred substitution pattern, -X-Z- R^1 is suitably aminocarbonylmethyl, pyrrolylmethyl or phenylmethyl substituted by cyano or methyl-oxadiazole.

Y is suitably a direct link, a 2,5-substituted oxazolyl group, or $-(CH_2)_n-O-$, where n is an integer from 0-3. More suitably, Y is a direct or oxy link. Preferably Y is a direct link.


- 5 R^2 is suitably cyclohexyl, a 5-6 membered aromatic heterocyclyl, e.g. pyrrolyl or pyridyl, or a phenyl group optionally substituted by one or two groups independently selected from halogen, e.g. fluoro or chloro, C_{1-4} alkyl, e.g. methyl, ethyl or isopropyl, C_{1-4} alkoxy, e.g. methoxy, or trifluoromethyl groups, where substitution is suitably in one or two of the 2-, 3-, or 4- positions on the phenyl
- 10 ring. Preferably, R^2 is a phenyl group substituted by a trifluoromethyl group, most preferably in the 4-position. Equally preferably, R^2 is a phenyl group substituted by an isopropyl group, most preferably in the 4-position.

- 15 Preferably, Y is a direct link and R^2 is a phenyl group substituted by a trifluoromethyl or isopropyl group, most preferably in the 4-position.

- R^3 is suitably hydrogen, halogen, e.g. chlorine, C_{1-4} alkyl, e.g. methyl, C_{1-3} perfluoroalkyl, e.g. trifluoromethyl or C_{1-4} alkoxy e.g. methoxy. R^3 is more suitably hydrogen, halogen, e.g. chlorine, C_{1-4} alkyl, e.g. methyl or C_{1-4} alkoxy e.g. methoxy. R^3 is preferably a hydrogen, methyl, methoxy or chloro group. R^3 is
- 20 equally preferably a hydrogen, methoxy or chloro group. Substitution is preferably in the 5 or 6 position.

- 25 Particularly preferred compounds of the invention include those in which each variable in Formula (I) is selected from the preferred groups for each variable. Even more preferable compounds of the invention include those where each variable in Formula (I) is selected from the more preferred or most preferred groups for each variable.

- 30 A suitable sub-group of a compound of formula (I) is represented by formula (Ia)



wherein

A is CH or N;

X is suitably C_{1-6} alkylene, optionally containing one double bond, oxo, sulfonyl, - C_{2-6} alkyleneoxy-, $-C_{1-6}$ alkylenecarboxy- or $-C_{1-6}$ alkylene(N-H or N- C_{1-6} alkyl)carboxamido;

Z represents a direct link or C_{1-6} alkylene ;

R^1 represents one of the following groups

(i) hydrogen, C_{1-3} perfluoroalkyl,

(ii) optionally substituted phenyl, where optional substitution is effected by one or two groups independently selected from C_{1-6} alkyl, cyano, halogen, C_{1-6} alkoxy, C_{1-3} perfluoroalkyl, hydroxycarbonyl, C_{1-4} alkoxycarbonyl, aminocarbonyl, C_{1-3} perfluoroalkylaminocarbonyl, methylenedioxy, nitro, C_{1-6} acyl, phenyl, or an optionally substituted aromatic heterocyclyl consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of 5 ring atoms, where optional substitution is effected by C_{1-4} alkyl, or C_{1-3} perfluoroalkyl,

(iii) an optionally substituted aromatic heterocyclyl consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of from 5-10 ring atoms, where optional substitution is effected by C_{1-4} alkyl, or C_{1-3} perfluoroalkyl; or

(iv) where either X is C_{1-6} alkylene and Z is a direct link, or Z is C_{1-6} alkylene, R^1 additionally may represent a cyano group;

Y represents a direct or oxy link, a 5-membered aromatic heterocyclyl group, - C_{1-6} alkylene- or -oxy C_{1-6} alkylene-;


R^2 represents phenyl, C_{3-6} cycloalkyl, or an aromatic heterocycle containing 5-6 ring atoms and 1-4 ring heteroatoms, where each ring is optionally substituted by one or more groups independently selected from halogen, C_{1-4} alkyl, C_{1-6} alkoxy, C_{1-3} perfluoroalkyl, hydroxycarbonyl, C_{1-4} alkoxycarbonyl, aminocarbonyl, C_{1-3} perfluoroalkylaminocarbonyl, methylenedioxy, nitro, C_{1-6} acyl, phenyl, or an optionally substituted aromatic heterocyclyl consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of 5 ring atoms, where optional substitution is effected by C_{1-4} alkyl, or C_{1-3} perfluoroalkyl;

C_{1-3} alkoxy or C_{1-3} perfluoroalkyl;

R^3 represents hydrogen, halogen, C_{1-4} alkyl or C_{1-4} alkoxy;
or a physiologically acceptable salt, solvate or derivative thereof.

5

A further suitable sub-group of a compound of formula (I) is represented by formula (Ib)



wherein

10

X is methylene, oxo or sulfonyl,

Z is selected from a direct link or NH,

provided that if X is a methylene group, Z is a direct link;

R^1 is selected from the following groups:

15

(i) hydrogen

(ii) C_{1-6} alkoxy, C_{1-6} alkylthio,

(iii) C_{1-6} alkylamino, di- C_{1-6} alkylamino C_{6-10} aryl C_{1-6} alkylamino, provided that Z is not NH,

(iv) unsubstituted vinyl, C_{6-10} aryl, C_{3-8} cycloalkyl, C_{3-8} cycloalkenyl,

(v) C_{6-10} aryloxy

20

(vi) heterocyclyl selected from the group consisting of 5- and 6- membered heterocyclic radicals, which may be saturated, partially saturated, or aromatic, and the fused benz derivatives thereof, wherein said radicals may contain a total of from 1 to 3 ring heteroatoms independently selected from oxygen, nitrogen and sulfur,

25

provided that if X is CH_2 , R^1 is selected from groups (iv) and (vi)

wherein, when R^1 contains one or more rings, said rings may each independently bear 0 to 3 substituents independently selected from halogen, hydroxy, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkylaminocarbonyl, di- C_{1-6} alkylamino,

30

di-C₁₋₆alkylaminocarbonyl, di-C₁₋₆alkylaminocarbonylC₁₋₆alkoxy, C₁₋₆acyl, C₁₋₆perfluoroalkoxy, C₁₋₆acyloxy, hydroxycarbonyl and C₁₋₆alkoxycarbonyl;


Y represents a bond, an oxazolyl group, -O-, a -C₁₋₆alkylene- or an -O-C₁₋₆alkylene- group;

R² represents phenyl, C₃₋₈cycloalkyl, or a heterocycle containing 5-6 ring atoms and 1-4 ring heteroatoms, where each ring is optionally substituted by one or more groups independently selected from halogen, C₁₋₄alkyl, C₁₋₄alkoxy, C₃₋₈cycloalkyl, C₁₋₃perfluoroalkyl, C₁₋₃perfluoroalkoxy, C₁₋₆alkoxycarbonyl, cyano, phenyl, phenoxy, benzyl, benzyloxy;

R³ represents hydrogen or one or two groups independently selected from halogen, C₁₋₄alkyl or C₁₋₄alkoxy groups;

or a physiologically acceptable salt, solvate or derivative thereof.

A yet further suitable sub-group of the invention is represented by a compound of formula (Ic)



wherein

X is methylene, oxo or sulfonyl,


R¹ represents phenyl or a 5-6 membered aromatic heterocyclic group, said groups being optionally substituted by one or two groups independently selected from C₁₋₈ alkyl, cyano, halogen, C₁₋₆ alkoxy, trifluoromethyl, hydroxycarbonyl and C₁₋₆alkoxycarbonyl;

R² represents phenyl substituted by one or two groups independently selected from halogen, trifluoromethyl, C₁₋₄alkyl or C₁₋₄alkoxy groups;

R³ represents hydrogen or one or two groups independently selected from halogen, C₁₋₄alkyl and C₁₋₄alkoxy groups;

or a physiologically acceptable salt, solvate or derivative thereof.

A yet further suitable sub-group of the invention is represented by a compound of formula (Id)



wherein


10 R^1 represents phenyl optionally substituted by one or two groups independently selected from C_{1-6} alkyl, cyano, halogen, C_{1-6} alkoxy, trifluoromethyl, hydroxycarbonyl and C_{1-6} alkoxycarbonyl;

R^2 represents phenyl substituted by one or two groups independently selected from halogen, trifluoromethyl, C_{1-4} alkyl and C_{1-4} alkoxy groups;

15 R^3 represents hydrogen or one or two groups independently selected from halogen, C_{1-4} alkyl and C_{1-4} alkoxy groups;

or a physiologically acceptable salt, solvate or derivative thereof.

A yet further suitable sub-group of the invention is represented by a compound of formula (Ie)



wherein

R^1 is selected from the following groups

25 (i) aminocarbonyl,

(ii) phenyl, optionally substituted by C₁₋₆ alkyl, cyano, halogen, C₁₋₆alkoxy, C₁₋₃perfluoroalkyl, hydroxycarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyl, methylenedioxy, nitro, C₁₋₆ acyl, phenyl, or an optionally substituted 5-membered aromatic heterocyclyl, where optional substitution is effected by C₁₋₄ alkyl or C₁₋₃perfluoroalkyl, or

(iii) an optionally substituted aromatic heterocyclyl consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of from 5-10 ring atoms, where optional substitution is effected by C₁₋₄ alkyl;

R² represents phenyl, optionally substituted by one or two groups independently selected from halogen, C₁₋₃perfluoroalkyl, C₁₋₄alkyl and C₁₋₄alkoxy groups;

R³ represents hydrogen, halogen, C₁₋₄alkyl or C₁₋₄alkoxy;

or a physiologically acceptable salt, solvate or derivative thereof.

It will be clear that references herein to a compound of formula (I) apply equally to a compound of formula (Ia)-(Ie).

Particularly preferred compounds of the invention include those in which each variable of formula (I) is selected from the suitable groups for each variable. Even more preferable compounds of the invention include those where each variable in formula (I) is selected from the preferred or more preferred groups for each variable.

Suitable compounds according to the invention include:

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

6-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

- 4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid [4-{3-(3-methyl-
[1,2,4]oxadiazol-5-yl)-benzyl]-piperazin-1-yl]-phenyl)-amide ;
5-Chloro-4'-isopropyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-
piperazin-1-yl]-phenyl]-amide ;
5 6-Methoxy-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-
piperazin-1-yl]-phenyl]-amide ;
5-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-
piperazin-1-yl]-phenyl]-amide ;
5-Chloro-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-
10 piperazin-1-yl]-phenyl]-amide ;
Biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
5-Methoxy-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-
phenyl]-amide;
4-Chloro-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-
15 piperazin-1-yl]-phenyl]-amide;
N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-phenoxy-benzamide;
N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-(5-phenyl-oxazol-2-yl)-
benzamide;
4'-Isopropyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-
20 phenyl]-amide;
5-Methoxy-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-
piperazin-1-yl]-phenyl]-amide;
4-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-
piperazin-1-yl]-phenyl]-amide;
25 4-Methoxy-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-
piperazin-1-yl]-phenyl]-amide;
4'-Ethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-
phenyl]-amide;
4'-Methoxy-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-
30 phenyl]-amide;
3'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-
yl]-phenyl]-amide;
4'-Fluoro-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-
phenyl]-amide;
35 3',4'-Dimethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-

- phenyl]-amide;
- 2',4'-Dimethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
- 3',4'-Dimethoxy-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
- 5 N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-(4-trifluoromethyl-benzyloxy)-benzamide ;
- N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-3-methoxy-2-(4-trifluoromethyl-benzyloxy)-benzamide ;
- 10 N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-(4-fluoro-benzyloxy)-3-methoxy-benzamide ;
- N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-3-methoxy-2-phenethyloxy-benzamide ;
- N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-(2-cyclohexyl-ethoxy)-3-methoxy-benzamide ;
- 15 N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-(2-cyclohexyl-ethoxy)-benzamide ;
- N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-3-methoxy-2-(3-phenyl-propoxy)-benzamide ;
- 20 N-4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-(4-fluoro-benzyloxy)-benzamide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [3-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 25 4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 30 6-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-cyanomethyl-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-ethoxycarbonylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 35

- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(2-ethoxy-ethyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-hydroxy-propyl)-piperazin-1-yl)-phenyl]-amide ;
- 5 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(4,4,4-trifluoro-butyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-methyl-but-2-enyl)-piperazin-1-yl)-phenyl]-amide ;
- 10 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-cyano-4-fluoro-benzyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3,4-methylenedioxy-benzyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-nitro-benzyl)-piperazin-1-yl)-phenyl]-amide ;
- 15 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-carbamoyl-benzyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-methoxy-benzyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(4-fluoro-benzyl)-piperazin-1-yl)-phenyl]-amide ;
- 20 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-fluoro-benzyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-benzyl)-piperazin-1-yl]-phenyl]-amide ;
- 25 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-carbomethoxy-benzyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-pyridin-4-ylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-pyridin-2-ylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 30 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-pyrazin-2-ylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-thiazol-2-ylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 35 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(1-methyl-1H-imidazol-2-

- ylmethyl)-piperazin-1-yl)-phenyl]-amide;
- 4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid (4-(4-(3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzyl)-piperazine-1-yl)-phenyl)-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide ;
- 5 4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide ;
- 5-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide ;
- 10 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-propyl-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-acetyl-benzyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-furan-2-ylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 15 4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(1-methyl-1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide ;
- 20 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-thiophen-2-ylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid {4-[4-(1H-pyrazole-3-ylmethyl)-piperazine-1-yl]-phenyl}-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-thiophen-3-ylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 25 4'-Trifluoromethyl-biphenyl-2-carboxylic acid {4-[4-(5-fluoro-1H-indol-3-ylmethyl)-piperazin-1-yl]-phenyl}-amide ;
- 4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid (4-(4-(3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzyl)-piperazine-1-yl)-phenyl)-amide ;
- 30 4'-Trifluoromethyl-biphenyl-2-carboxylic acid (4-{4-[3-(5-trifluoromethyl-[1,2,4]oxadiazol-3-yl)-benzyl]-piperazin-1-yl}-phenyl)-amide ;
- (4-{4-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazin-1-yl)-acetic acid ;
- 4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-[(biphenyl-3-ylmethyl)-carbamoyl]-methyl)-piperazin-1-yl)-phenyl]-amide ;
- 35

3-(4-{4-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazin-1-ylmethyl)-benzoic acid ;

4'-Trifluoromethyl-biphenyl-2-carboxylic acid (4-{4-[3-(2,2,2-trifluoroethylcarbamoyl)-benzyl]-piperazin-1-yl}-phenyl)-amide;

5 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-{4-(3-cyano-benzoyl)-piperazin-1-yl}-phenyl]-amide ;

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-acetyl-piperazin-1-yl)-phenyl]-amide ;

10 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-{4-(3-cyano-benzenesulfonyl)-piperazin-1-yl}-phenyl]-amide ;

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-methanesulfonyl-piperazin-1-yl)-phenyl]-amide ;

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-{1-(3-cyano-benzyl)-piperidin-4-yl}-phenyl]-amide ;

15 N-{4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl}-2-pyrrol-1-yl-benzamide ;

N-{4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl}-2-pyridin-2-yl-benzamide ;

or a physiologically acceptable salt, solvate or derivative thereof.

Preferred compounds of the invention include:

20 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-{4-(3-cyano-benzyl)-piperazin-1-yl}-phenyl]-amide ;

4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid [4-{4-(3-cyano-benzyl)-piperazin-1-yl}-phenyl]-amide ;

25 4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid [4-{4-(3-cyano-benzyl)-piperazin-1-yl}-phenyl]-amide ;

4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid [4-{4-(3-cyano-benzyl)-piperazin-1-yl}-phenyl]-amide ;

6-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-{4-(3-cyano-benzyl)-piperazin-1-yl}-phenyl]-amide ;

30 4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid (4-{3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzyl}-piperazin-1-yl)-phenyl)-amide ;

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide ;

35 4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide ;

4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide ;

4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid (4-(4-(3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzyl)-piperazine-1-yl)-phenyl)-amide ;

5 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide ;

4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide ;

10 5-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide ;

or a physiologically acceptable salt, solvate or derivative thereof.

15 The term "physiologically functional derivative" as used herein refers to any physiologically acceptable derivative of a compound of the present invention, for example, an ester, which upon administration to a mammal, such as a human, is capable of providing (directly or indirectly) such a compound or an active metabolite thereof. Such derivatives are clear to those skilled in the art, without undue experimentation, and with reference to the teaching of Burger's Medicinal Chemistry And Drug Discovery, 5th Edition, Vol 1: Principles And Practice, 20 which is incorporated herein by reference.

25 The compounds of the invention are inhibitors of hepatic production of apoB-100 and are thus of use in the treatment of conditions resulting from elevated circulating levels of apoB-100.

30 The ability of the compounds of the invention to inhibit the production of apoB-100 by human hepatocytes in vitro is determined using primary human hepatocytes as a model system. The specificity of the compounds of the invention is established by comparing the effects on apoB-100, apoprotein A-1, and fibrinogen production. A specificity of at least 100 is preferred.

35 The in vivo profile of the compounds was determined by acute oral administration of the compounds of the invention to DBA/2 mice and Wistar rats with measurement of apoB-100 plasmatic levels as percentage of control values. Active compounds are further evaluated in Wistar rats by repeated oral

administration (once a day) with measurement of total cholesterol, low density lipoprotein-cholesterol, triglycerides, apoB-100 and apoA-I plasmatic levels as a percentage of control values.

5 The compounds of the invention are potent and specific inhibitors of hepatic production of apoB-100, which furthermore exhibit good oral bioavailability and duration of action.

10 Compounds of the invention are of use in the treatment of atherosclerosis, pancreatitis, non-insulin dependent diabetes mellitus (NIDDM), and coronary heart diseases.

15 Compounds of the invention are also useful in lowering serum lipid levels, cholesterol and/or triglycerides, and are of use in the treatment of hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholesterolemia and/or hypertriglyceridemia.

20 The invention therefore provides a compound of formula (I) or a physiologically acceptable salt, solvate or derivative thereof for use in therapy, in particular in human medicine.

25 There is also provided as a further aspect of the invention the use of a compound of formula (I) or a physiologically acceptable salt, solvate or derivative thereof in the preparation of a medicament for use in the treatment of conditions resulting from elevated circulating levels of apoB-100.

30 In an alternative or further aspect there is provided a method for the treatment of a mammal, including man, in particular in the treatment of conditions resulting from elevated circulating levels of apoB-100, comprising administration of an effective amount of a compound of formula (I) or a physiologically acceptable salt, solvate or derivative thereof.

It will be appreciated that reference to treatment is intended to include prophylaxis as well as the alleviation of established symptoms. Compounds of

formula (I) may be administered as the raw chemical but the active ingredient is preferably presented as a pharmaceutical formulation.

5 Accordingly, the invention also provides a pharmaceutical composition which comprises at least one compound of formula (I) or a physiologically acceptable salt, solvate or derivative thereof and formulated for administration by any convenient route. Such compositions are preferably in a form adapted for use in medicine, in particular human medicine, and can conveniently be formulated in a conventional manner using one or more pharmaceutically acceptable carriers or
10 excipients.

Thus compounds of formula (I) may be formulated for oral, buccal, parenteral, transdermal, topical (including ophthalmic and nasal), depot or rectal administration or in a form suitable for administration by inhalation or insufflation
15 (either through the mouth or nose).

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl
20 methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known
25 in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents
30 (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

5 For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.

10 For transdermal administration the compounds according to the invention may be formulated as creams, gels, ointments or lotions or as a transdermal patch. Such compositions may for example be formulated with an aqueous or oily base with the addition of suitable thickening, gelling, emulsifying, stabilising, dispersing, suspending, and/or colouring agents.

15 The compounds of the invention may be formulated for parenteral administration by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

20 The compounds of the invention may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops). Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.

25 Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.

The compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

5 The compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an
10 acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

For intranasal administration, the compounds of the invention may be formulated as solutions for administration via a suitable metered or unit dose
15 device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.


The compositions may contain from 0.1% upwards, e.g. 0.1 - 99% of the active material, depending on the method of administration. A proposed dose of the
20 compounds of the invention is 0.25mg/kg to about 125mg/kg bodyweight per day e.g. 20mg/kg to 100mg/kg per day. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient and the precise dosage will be ultimately at the discretion of the attendant physician or veterinarian. The dosage will also
25 depend on the route of administration and the particular compound selected.

The compounds of formula (I) may, if desired, be administered with one or more therapeutic agents and formulated for administration by any convenient route in a conventional manner. Appropriate doses will be readily appreciated by those
30 skilled in the art. For example, the compounds of formula (I) may be administered in combination with an HMG CoA reductase inhibitor.

A compound of formula (I), or a physiologically acceptable salt, solvate or derivative thereof, may be prepared by the general methods outlined hereafter.


In the following description, the groups X, Y, Z, R¹, R² and R³ are as previously defined for compounds of formula (I), unless specified otherwise.

- 5 According to a general process (A), a compound of formula (I) may be prepared by reacting a compound of formula (II) with a compound of formula R¹-Z-X-L



- 10 where L represents a suitable halide leaving group, e.g. chloride, under standard displacement conditions, or where X is an oxo group, L may additionally represent a hydroxy group, the reaction being effected under standard acid and amine coupling conditions.


- 15 A compound of formula (II) may be prepared by reaction of a compound of formula (III) with a compound of formula (IV)



- 20 where L is defined above and P is a suitable amine protecting group, e.g. tert-butoxycarbonyl (Boc), under standard coupling conditions for an acid and amine coupling, followed by deprotection of the protecting group under suitable conditions, e.g. acidic removal of a Boc group.

A compound of formula (IV), where A represents N, may be prepared by the two step reaction of a compound of formula (V)


24



comprising incorporation of the protecting group P using standard methodology followed by reduction of the nitro group, e.g. under hydrogenation conditions.

5

A compound of formula (IV), where A represents CH, may be prepared from a compound of formula (VI)




10

by reaction with a suitable compound of formula H_2N-P' where P' is a suitable protecting group which is labile under hydrogenation conditions, such as a benzyl group, using a suitable coupling agent or agents such as tris(dibenzylidene acetone)dipalladium, 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (binap) and sodium tert-butoxide in a suitable solvent such as toluene, followed by removal of the protecting group and reduction of the double bond under hydrogenation conditions.

15

According to a second method (B), compounds of formula (I) may be prepared by reaction of compounds of formula (III) and compounds of formula (VII)

20




where L is defined above, under standard coupling conditions.

25


Compounds of formula (VII) may be prepared by reaction of a compound of formula (V) with a compound of formula $R^1-Z-X-L$, where L is defined above, followed by reduction of the nitro group under hydrogenation or reductive tin chloride conditions.

According to a third process (C), a compound of formula (I) where Y is -O-C₁₋₄alkylene- may be prepared by reaction of a compound of formula (VIII) with a compound of formula R²-C₁₋₄alkylene-L, where L is defined above.



Compounds of formula (VIII) may be prepared according to the process outlined in process B.


According to a fourth general process (D), a compound of formula (I), where at least part of X represents an alkylene link to the piperidine or piperazine group, may be prepared by reacting a compound of formula (II) with a compound of formula (IX)



where X' represents X minus a methylene group, under standard reductive amination conditions, e.g. using sodium triacetoxyborohydride in a solvent such as dichloroethane.

According to a fifth process (E), a compound of formula (I) may be prepared from a different compound of formula (I), using standard techniques well known in the art. For example, compounds of formula (I) where R^1 comprises a group containing an amide group may be prepared from the compound of formula (I) where the corresponding position comprises a carboxylic acid group, which in turn may be prepared from the compound of formula (I) where the corresponding position comprises a carboxylic ester group. Well known methods in the art may be employed to facilitate the transformation of an ester to an acid and then to an amide.

A compound of formula (III), where Y is a direct link, R^2 is a phenyl or an aromatic heterocyclyl and L is a hydroxy group, may be prepared firstly by coupling a boronic acid with a suitable leaving group, represented by a compound of formula (X) and a compound of formula (XI)



where R^2 represents phenyl or an aromatic heterocyclyl, PG represents a protected carboxylic acid and A and D represent either the boronic acid or the suitable leaving group, such as triflate or bromide, followed by deprotection of the protecting group under standard conditions, such as base removal of an ester group. Where L represents a halide leaving group, the carboxylic acid product can be treated with a suitable reagent, such as thionyl chloride, to give the corresponding chloride leaving group.

Where R^1 is a phenyl, substituted by an aromatic heterocyclyl, the aromatic heterocyclyl may be introduced by any well known methods in the art. For instance, where the substituent is a methyl substituted oxadiazole, this may be formed by treatment of a suitable benzamide derivative with a suitable reagent, such as dimethylacetamide dimethylacetal at elevated temperature, followed by cyclisation of the intermediate compound with hydroxylamine.

The various general methods described above may be useful for the introduction of the desired groups at any stage in the stepwise formation of the required compound, and it will be appreciated that these general methods can be combined in different ways in such multi-stage processes. The sequence of the reactions in multi-stage processes should of course be chosen so that the reaction conditions used do not affect groups in the molecule which are desired in the final product.

Compounds of formula $R^1-Z-X-L$, (III), (V) and (VI), (IX), (X) and (XI) are known or may be prepared by standard methods well known in the art and/or herein described.

Physiologically acceptable salts may also be prepared from other salts, including other physiologically acceptable salts, of the compound of formula (I) using conventional methods.

The compounds of formula (I) may readily be isolated in association with solvent molecules by crystallisation from or evaporation of an appropriate solvent to give the corresponding solvates.

When a specific enantiomer of a compound of general formula (I) is required, this may be obtained for example by resolution of a corresponding enantiomeric mixture of a compound of formula (I) using conventional methods.

Thus, in one example an appropriate optically active acid may be used to form salts with the enantiomeric mixture of a compound of general formula (I). The resulting mixture of isomeric salts may be separated, for example, by fractional crystallisation into the diastereoisomeric salts from which the required enantiomer of a compound of general formula (I) may be isolated by conversion into the required free base.

Alternatively, enantiomers of a compound of general formula (I) may be synthesised from the appropriate optically active intermediates using any of the general processes described herein.

The invention is further illustrated by the following intermediates and examples. All temperatures are in degrees centigrade.

Abbreviations:

MS - LCMS mass spectrography, HOBt-1-Hydroxybenzotriazole, AcOEt-Ethyl acetate, EDCI-1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, BINAP-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, THF- Tetrahydrofuran, MeOH- Methanol, EtOH- Ethanol, Et₃N- Triethylamine

Intermediate 1

5-Methoxy-4'-trifluoromethyl-biphenyl-2-carboxylic acid methyl ester

To a stirred solution of 4-methoxy-2-(trifluoro-methanesulfonyloxy)-benzoic acid methyl ester (6.28 g) in toluene (100 mL) was added LiCl (2.54 g) and Pd(PPh₃)₄ (1.15 g). After few minutes at room temperature, a 2M solution of Na₂CO₃ (26 mL) was added followed by a solution of 4-trifluoromethylphenyl boronic acid (4.17 g) in EtOH (30 mL). The resulting mixture was stirred under reflux for 6 hours. The mixture was cooled to room temperature and the phases were separated. The organic layer was then dried over Na₂SO₄, filtered and evaporated under reduced pressure. The residue was purified by flash chromatography eluting with hexane/AcOEt (90/10) to give the title compound (5.7 g) as white crystals.
m.p. : 93-94°C.

Similarly prepared were :

Intermediate 2

4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid methyl ester as an oil (10 g),
GCMS : m/z 268 (M+)
from 4-methyl-2-(trifluoro-methanesulfonyloxy)-benzoic acid methyl ester (11.9 g) and 4-isopropylphenyl boronic acid (7.2 g).

Intermediate 3

5-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid methyl ester as a pale yellow oil (4.2 g),
GCMS : m/z 294(M+)
from 4-methyl-2-(trifluoro-methanesulfonyloxy)-benzoic acid methyl ester (4.7 g)

and 4-trifluoromethylphenyl boronic acid (3.3 g).

Intermediate 4

5 6-Methoxy-4'-trifluoromethyl-biphenyl-2-carboxylic acid methyl ester as an oil (6.8 g),

GCMS : m/z 310 (M+)

from 3-methoxy-2-(trifluoro-methanesulfonyloxy)-benzoic acid methyl ester (8.6 g) and 4-trifluoromethylphenyl boronic acid (5 g).

10 Intermediate 5

4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid methyl ester as an oil (10 g),

GCMS : m/z 284 (M+)

from 3-methoxy-2-(trifluoro-methanesulfonyloxy)-benzoic acid methyl ester (12.2 g) and 4-isopropylphenyl boronic acid (7 g).

15 Intermediate 6

4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid methyl ester as a colorless oil (15.3 g),

GCMS : m/z 268 (M+)

20 from 3-methyl-2-(trifluoro-methanesulfonyloxy)-benzoic acid methyl ester (15.7 g) and 4-isopropylphenyl boronic acid (10 g).

Intermediate 7

25 6-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid methyl ester as a colorless oil (13.7 g),

GCMS : m/z 294 (M+)

from 3-methyl-2-(trifluoro-methanesulfonyloxy)-benzoic acid methyl ester (15.7 g) and 4-trifluoromethylphenyl boronic acid (10 g).

30 Intermediate 8

2-(4'-Isopropyl-5-methoxy-biphenyl-2-yl)-4,4-dimethyl-4,5-dihydro-oxazole

To a suspension of magnesium (0.69 g) in Et₂O (5 mL) containing a trace of iodine was added dropwise a solution of 1-bromo-4-isopropyl-benzene (5.97 g) in Et₂O (50 mL). Following the addition, the mixture was heated under reflux for 35 1 hour. The resulting grignard solution was then carefully added to a solution

of 2-(2,4-dimethoxy-phenyl)-4,4-dimethyl-4,5-dihydro-oxazole (3.52 g) in THF (60 mL) and the mixture was stirred at room temperature for 16 hours. The reaction mixture was then poured into saturated aqueous solution of NH_4Cl and the mixture was extracted with Et_2O , dried over Na_2SO_4 , filtered and evaporated under reduced pressure. The residue was purified by flash chromatography eluting with $\text{CH}_2\text{Cl}_2/\text{AcOEt}$ (85/15) to give the title compound (3.5 g) as a pale yellow oil.

MS : m/z 324 (M+1).

Similarly prepared was :

Intermediate 9

2-(5-Chloro-4'-isopropyl-biphenyl-2-yl)-4,4-dimethyl-4,5-dihydro-oxazole as a yellow oil (7.5 g),

MS : m/z 326 (M-1)

from 2-(4-chloro-2-methoxy-phenyl)-4,4-dimethyl-4,5-dihydro-oxazole (10.2 g) and 1-bromo-4-isopropyl-benzene (17.3 g).

Intermediate 10

5'-Chloro-2'-methyl-4-trifluoromethyl-biphenyl

To a solution of 2-bromo-4-chloro-toluene (20.5 g) in toluene (100 mL) was added $\text{Pd}(\text{PPh}_3)_4$ (1 g) and the mixture was stirred at room temperature under N_2 for 0.25 hours. A 2M solution of Na_2CO_3 (100 mL) was then added, followed by the dropwise addition of 4-trifluoromethylphenyl boronic acid (19 g) in MeOH (100 mL). The resulting mixture was heated under reflux for 48 hours. The mixture was then cooled to room temperature and the phases were separated. The organic layer was then dried over Na_2SO_4 , filtered and evaporated under reduced pressure. The residue was purified by flash chromatography eluting with petroleum ether/AcOEt (90/10) to give the title compound (25.3 g) as a colorless liquid.

GCMS : m/z 270 (M+).

Intermediate 11

5-Methoxy-4'-trifluoromethyl-biphenyl-2-carboxylic acid

5-Methoxy-4'-trifluoromethyl-biphenyl-2-carboxylic acid methyl ester (5.6 g) was placed in suspension in EtOH (80 mL) and a solution of NaOH (2.9 g) in water (40 mL) was added. The mixture was stirred under reflux for 2 hours and EtOH was evaporated under reduced pressure. The aqueous layer was then acidified with concentrated HCl and the resulting solid which formed was filtered, washed with water and dried to give the title compound (5.1 g) as white crystals.
m.p. : 232-234°C.

Similarly prepared were :

Intermediate 12

4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid as white crystals (9 g),
m.p. : 109-111°C
from 4'-isopropyl-5-methyl-biphenyl-2-carboxylic acid methyl ester (10 g).

Intermediate 13

5-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid as white crystals (3.7 g),
m.p. : 176-178°C
from 5-methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid methyl ester (4.2 g).

Intermediate 14

6-Methoxy-4'-trifluoromethyl-biphenyl-2-carboxylic acid as white crystals (2.5 g),
m.p. : 207-209°C
from 6-methoxy-4'-trifluoromethyl-biphenyl-2-carboxylic acid methyl ester (6.8 g).

Intermediate 15

4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid as white crystals (8.4 g),
m.p. : 132-134°C
from 4'-isopropyl-6-methoxy-biphenyl-2-carboxylic acid methyl ester (10 g).

Intermediate 16

4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid as white crystals (10 g),
m.p. : 145-146°C
from 4'-isopropyl-6-methyl-biphenyl-2-carboxylic acid methyl ester (15.3 g).

Intermediate 17

6-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid as white crystals (8.5 g),
m.p. : 206-208°C

5 from 6-methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid methyl ester (10 g).

Intermediate 18

4'-Isopropyl-5-methoxy-biphenyl-2-carboxylic acid

10 A solution of 2-(4'-isopropyl-5-methoxy-biphenyl-2-yl)-4,4-dimethyl-4,5-dihydro-oxazole (3.4 g) in 4.5N HCl (200 mL) was stirred under reflux for 48 hours. The mixture was then cooled to room temperature and was extracted with Et₂O. The organic phase was then washed with brine, dried over Na₂SO₄, filtered and evaporated under reduced pressure to give the title compound (2.5 g) as an off white solid.

15 m.p. : 188-190°C.

Similarly prepared was :

Intermediate 19

20 5-Chloro-4'-isopropyl-biphenyl-2-carboxylic acid as white crystals (2.2 g),

m.p.: 145-147°C

from 2-(5-chloro-4'-isopropyl-biphenyl-2-yl)-4,4-dimethyl-4,5-dihydro-oxazole (7.5 g).

25 Intermediate 20

5-Chloro-4'-trifluoromethyl-biphenyl-2-carboxylic acid

30 To a solution of 5'-chloro-2'-methyl-4-trifluoromethyl-biphenyl (27 g) in a mixture of t-butanol (100 mL) and H₂O (200 mL) was added portionwise KMnO₄ (46.9 g). At the end of the addition, the mixture was heated under reflux for 16 hours, cooled to room temperature and filtered on celite. The filtrate was then acidified with concentrated HCl and the aqueous layer was extracted with AcOEt. The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered and evaporated under reduced pressure to give the title compound (24 g) as white crystals.

35 m.p. : 174-176°C.

Intermediate 211-(3-Cyano-benzyl)-4-(4-nitro-phenyl)-piperazine

To a stirred solution of 1-(4-nitro-phenyl)-piperazine (35.9 g) and potassium carbonate (71.6 g) in acetone (500 mL) was added dropwise 3-cyano-benzyl bromide (34 g) at room temperature and the mixture was heated under reflux. After 4 hours, the salts were removed by filtration, washed with acetone and the filtrate was evaporated to dryness. The residue was taken in CH_2Cl_2 and the solution was washed with water, dried over Na_2SO_4 , filtered and evaporated. The oily residue was crystallized from AcOEt/diisopropyl ether to give the title compound (52 g) as orange crystals.
m.p. : 120-122°C.

Intermediate 224-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenylamine

To a stirred solution of 1-(3-cyano-benzyl)-4-(4-nitro-phenyl)-piperazine (52 g) in EtOH (1.2 L) and THF (300 mL) was added portionwise $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ (145.6 g) at room temperature and the mixture was heated at 55°C for 16 hours. After evaporation of the solvents, the residue was taken in water, basified with NaOH at pH 14 and extracted with CH_2Cl_2 . The organic layer was then washed with water, dried over Na_2SO_4 , and evaporated. The residue was crystallized from diisopropyl ether to give the title compound (40.5 g) as pale yellow crystals.
m.p. : 99-101°C.

Intermediate 23N-[4-[3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-hydroxy-benzamide

To a stirred solution of 4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenylamine (2.24 g), 2-hydroxy-benzoic acid (1.08 g), HOBt (1.35 g), and Et₃N (1 g) in CH_2Cl_2 (70 mL) was added at room temperature EDCI (1.9 g) and the mixture was stirred at room temperature for 4 hours. The organic solution was then washed with water, with a saturated solution of NaHCO_3 , with brine and dried over Na_2SO_4 . After filtration and evaporation of the filtrate, the residue was purified by flash chromatography eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (98/2) to give the title compound (1.85 g) as a yellow solid.

m.p. : 79-81°C.

Similarly prepared was :

Intermediate 24

5 N-[4-[3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-hydroxy-3-methoxy-benzamide
as pale yellow crystals (3.4 g),
m.p. : 160-162°C
from 4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenylamine (4.39 g) and 2-hydroxy-
3-methoxy-benzoic acid (2.56 g).

10

Intermediate 25

4-(4-Nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester

To a solution of 1-(4-nitro-phenyl)-piperazine (15.5 g) in CH_2Cl_2 (250 mL) was
added Et_3N (8.3 g). The solution was cooled to 0°C and di-tert-butyl dicarbonate
15 (17.1 g) was added portionwise. After 16 hours at room temperature, the
solution was washed with water, with a saturated solution of NaHCO_3 and brine.
The organic phase was dried over Na_2SO_4 , filtered and evaporated under
reduced pressure and the resulting solid was recrystallized from MeOH to give
the title compound (21.5 g) as pale yellow crystals.
20 m.p. : 149-151°C.

Intermediate 26

4-(3-Nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester

To a solution of 1-iodo-3-nitro-benzene (9 g), piperazine-1-carboxylic acid tert-
25 butyl ester (13.5 g) and sodium tert-butoxide (9.7 g) in dioxane (150 mL) was
added tris(dibenzylideneacetone)dipalladium (2 g) and tri-o-tolylphosphine (2.2
g) and the mixture was heated at reflux for 24 hours. The solution was then
cooled to room temperature, taken in Et_2O and washed with brine. The organic
layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure.
30 The crude residue was recrystallized from diisopropyl ether to give the title
compound (6 g) as a yellow solid.
m.p. : 126-128°C.

Intermediate 27

35 4-(4-Amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester

A solution of 4-(4-nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (21.4 g) in EtOH (250 mL) containing Pd/C 10% (0.5 g) was hydrogenated at room temperature. After 16 hours, the catalyst was removed by filtration and the filtrate was evaporated under reduced pressure. The oily residue was then crystallized from cyclohexane to give the title compound (17.8 g) as pink crystals.

m.p. : 95-96°C.

Similarly prepared was :

Intermediate 28

4-(3-Amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester as an oil (2.5 g),

MS : m/z 278(M+1)

from 4-(3-nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (6 g).

Intermediate 29

4-{4-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester

Method A :

To a stirred solution of 4-(4-amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (1.38 g), 4'-trifluoromethyl-biphenyl-2-carboxylic acid (1.33 g), HOBt (0.81 g), and Et₃N (0.6 g) in CH₂Cl₂ (30 mL) was added EDCI (1.15 g) and the mixture was stirred at room temperature for 6 hours. The organic solution was then washed with water, with a saturated solution of NaHCO₃ and dried over Na₂SO₄. After filtration and evaporation of the filtrate, the residue was purified by flash chromatography eluting with CH₂Cl₂/AcOEt (90/10) and the resulting oily compound was crystallized from EtOH to give the title compound (2.3 g) as white crystals.

m.p.: 214-215°C.

Method B :

To a stirred solution of 4-(4-amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (8.1 g) in CH₂Cl₂ (150 mL) was added Et₃N (3.33 g) and the mixture was cooled at 0°C. To this solution was added dropwise 4'-trifluoromethyl-biphenyl-2-carbonyl chloride (8.53 g) in CH₂Cl₂ (80 mL) and the mixture was stirred at

room temperature for 1 hour. The organic solution was then sequentially washed with water, with a saturated solution of NaHCO_3 , with brine, then dried over Na_2SO_4 , filtered and evaporated. The oily residue by trituration from diisopropyl ether give the title compound (13.6 g) as white crystals.

m.p. : 213-215°C.

Intermediate 30

4-{4-[(4'-isopropyl-5-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester

To a stirred solution of 4-(4-amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (4.15 g), 4'-isopropyl-5-methyl-biphenyl-2-carboxylic acid (3.81 g), HOBt (2.36 g), and Et_3N (1.97 g) in CH_2Cl_2 (50 mL) was added EDCI (3.72 g) and the mixture was stirred at room temperature for 16 hours. The organic solution was then washed with water, with a saturated solution of NaHCO_3 , with brine and dried over Na_2SO_4 . After filtration and evaporation of the filtrate, the residue was crystallized from diisopropyl ether to give the title compound (4 g) as white crystals.

m.p.: 173-175°C.

Similarly prepared were :

Intermediate 31

4-{4-[(4'-isopropyl-6-methoxy-biphenyl-2-carbonyl)-amino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester as white crystals (1.9 g),

m.p. : 155-157°C

from 4'-isopropyl-6-methoxy-biphenyl-2-carboxylic acid (1.94 g) and 4-(4-amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (2 g).

Intermediate 32

4-{4-[(6-Methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester as white crystals (1.5 g),

m.p. : 163-165°C

from 6-methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid (2 g) and 4-(4-amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (2 g).

Intermediate 33

4-{4-[(4'-Isopropyl-6-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester as white crystals (1.8 g),
m.p. : 140-142°C

- 5 from 4'-isopropyl-6-methyl-biphenyl-2-carboxylic acid (1.83 g) and 4-(4-amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (2 g).

Intermediate 34

10 4-{4-[2-(4-Fluoro-benzyloxy)-benzoylamino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester as white crystals (6.7 g),
m.p. : 170-171°C

from 4-(4-amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (4.15 g) and 2-(4-fluoro-benzyloxy)-benzoic acid (3.69 g).

15 Intermediate 35

4-{3-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester as a white solid (3.3 g),
m.p. : 160°C

- 20 from 4-(3-amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester (2.5 g) and 4'-trifluoromethyl-biphenyl-2-carboxylic acid (2.5 g).

Intermediate 36

4'-Trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide

- 25 To a solution of 4-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester (11.7 g) in CH₂Cl₂ (50 mL) was added trifluoroacetic acid (25 mL) and the solution was stirred at room temperature for 2 hours. The mixture was then evaporated under reduced pressure and the residue was taken in water. The resulting precipitate was filtered and washed with water. The resulting solid was then suspended in
30 water, basified with a saturated solution of Na₂CO₃, and extracted with CH₂Cl₂. The organic phase was then washed with water, dried over Na₂SO₄, filtered and evaporated to give the title compound (9 g) as white crystals.
m.p.: 119-124°C.

35 Intermediate 37

4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide

To a solution of 4-{4-[(4'-isopropyl-5-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester (4 g) in CH₂Cl₂ (20 mL) was added trifluoroacetic acid (15 mL) and the solution was stirred at room temperature for 16 hours. The mixture was then evaporated under reduced pressure and the residue was taken in water and basified with a 1N NaOH aqueous solution. The resulting precipitate was extracted with CH₂Cl₂ and the organic phase was washed with water, dried over Na₂SO₄, filtered and evaporated to give the title compound (3 g) as white crystals.
m.p.: 131-133°C.

Similarly prepared were

Intermediate 38

4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide as white crystals (1.3 g),

m.p. : 157-159°C

from 4-{4-[(4'-isopropyl-6-methoxy-biphenyl-2-carbonyl)-amino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester (1.9 g).

Intermediate 39

6-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide as white crystals (0.9 g),

m.p. : 155-157°C

from 4-{4-[(6-methyl-4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester (1.5 g).

Intermediate 40

4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide as white crystals (1.2 g),

m.p. : 130°C

from 4-{4-[(4'-isopropyl-6-methyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester (1.8 g).

Intermediate 41

2-(4-Fluoro-benzyloxy)-N-(4-piperazin-1-yl-phenyl)-benzamide as white crystals (3.6 g),

m.p. : 143-146°C

from 4-{4-[2-(4-fluoro-benzyloxy)-benzoylamino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester (6 g).

Intermediate 42

4'-Trifluoromethyl-biphenyl-2-carboxylic acid (3-piperazin-1-yl-phenyl)-amide as white crystals (2.5 g),

m.p. : 101-103°C

from 4-{3-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazine-1-carboxylic acid tert-butyl ester (3.3 g).

Intermediate 43

4-(4-Bromo-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester

To a solution of 4-(4-bromo-phenyl)-1,2,3,6-tetrahydro-pyridine (2.39 g) in CH₂Cl₂ (30 mL) was added Et₃N (2 g). The solution was cooled at 0°C and di-tert-butyl dicarbonate (2.29 g) was added. After 16 hours at room temperature, the solution was washed with water, with a saturated solution of NaHCO₃ and brine. The organic phase was dried over Na₂SO₄, filtered and evaporated under reduced pressure and the residue was purified by flash chromatography eluting with CH₂Cl₂ to give the title compound (2 g) as a white solid.

m.p. : 68-70°C.

Intermediate 44

4-(4-Benzylamino-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester

To a solution of 4-(4-bromo-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (0.34 g), benzylamine (0.12 g) and sodium tert-butoxide (0.13 g) in toluene (8 mL) were added tris(dibenzylidene acetone)dipalladium (2.2 mg) and Binap (4.6 mg) and the mixture was heated at 80°C for 16 hours. The solution was then cooled to room temperature, filtered and the filtrate was evaporated under reduced pressure. The residue was purified by flash chromatography eluting with petroleum ether/AcOEt (90/10) and the oily residue

was crystallized from diisopropyl ether to give the title compound (0.27 g) as white crystals.

m.p. : 120-121°C.

5 Intermediate 45

4-(4-Aminophenyl)-piperidine-1-carboxylic acid tert-butyl ester

A solution of 4-(4-benzylamino-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (0.27 g) in EtOH (10 mL) containing Pd/C 10% (50 mg) was hydrogenated at room temperature. After 1 hour, the catalyst was removed by
10 filtration and the filtrate was evaporated under reduced pressure to give the title compound (0.18 g) as a pale pink oil.

MS : m/z 277(M+1).

Intermediate 46

15 4-{4-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperidine-1-carboxylic acid tert-butyl ester

To a stirred solution of 4-(4-aminophenyl)-piperidine-1-carboxylic acid tert-butyl ester (0.18 g), 4'-trifluoromethyl-biphenyl-2-carboxylic acid (0.17 g), HOBT (0.1 g), and Et₃N (80 mg) in CH₂Cl₂ (10 mL) was added at room temperature EDCI
20 (0.15 g) and the mixture was stirred at room temperature for 16 hours. The organic solution was then washed with water, with a saturated solution of NaHCO₃, and dried over Na₂SO₄. After filtration and evaporation of the filtrate, the residue was purified by flash chromatography eluting with petroleum ether/AcOEt (70/30) to give the title compound (0.25 g) as an orange oil.

25 MS : m/z 523(M-1).

Intermediate 47

4'-Trifluoromethyl-biphenyl-2-carboxylic acid (4-piperidin-4-yl-phenyl)-amide as trifluoroacetate salt

30 To a solution of 4-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperidine-1-carboxylic acid tert-butyl ester (0.22 g) in CH₂Cl₂ (5 mL) was added trifluoroacetic acid (1 mL) and the solution was stirred at room temperature for 1 hour. The mixture was evaporated under reduced pressure and the residue taken in water. The resulting precipitate was filtered, washed with water and
35 dried to give the title compound (0.23 g) as white crystals.

m.p.: 223-225°C.

Intermediate 48

3-[1,3]Dioxolan-2-yl-benzamide

5 To a solution of 3-(1,3-dioxolan-2-yl)-benzonitrile (5.86 g) in a mixture of EtOH (140 mL) and H₂O (60 mL) was added sodium hydroxide (6.46 g) and the mixture was heated under reflux for 2 hours. The solvent was evaporated under reduced pressure and the aqueous layer was extracted with CH₂Cl₂. The organic phase was washed with water, dried over Na₂SO₄, filtered and evaporated to
10 give the title compound (4.5 g) as a white solid.
m.p. : 92-94°C.

Intermediate 49

3-(3-Methyl-[1,2,4]oxadiazol-5-yl)-benzaldehyde

15 A mixture of 3-[1,3]dioxolan-2-yl-benzamide (2.3 g) and dimethylacetamide dimethylacetal (4 g) was heated under reflux for 1 hour and then evaporated to dryness. The oily residue was dissolved in dioxane (20 mL) and hydroxylamine hydrochloride (1.18 g), acetic acid (20 mL) and a 2N aqueous sodium hydroxide solution (9 mL) were added and the mixture was heated at 90°C for 2 hours.
20 After evaporation, the residue was dissolved in toluene (100 mL) and a 1N hydrochloric acid solution (50 mL) was added and the mixture was stirred at reflux for 2 hours. After cooling at room temperature the organic phase was decanted, washed with water, dried over Na₂SO₄, filtered and evaporated to give the title compound (2.3 g) as a white solid.
25 m.p. : 114-116°C.

Intermediate 50

[4-(4-Benzyl-piperazine-1-yl)-phenyl]-carbamic acid tert-butyl ester

30 To a solution of 4-(4-benzyl-piperazine-1-yl)-phenylamine (32 g) in CH₂Cl₂ (500 mL) containing Et₃N (18.4 mL) was added dropwise di-tert-butyl dicarbonate (28.8 g) at 0°C. After 20 hours at room temperature, the solution was washed with water, with a saturated solution of NaHCO₃ and brine. The organic phase was dried over Na₂SO₄, filtered and evaporated under reduced pressure to give the title compound (43.5 g) as a solid.
35 GCMS : m/z 367 (M+).

Intermediate 51(4-Piperazin-1-yl-phenyl)-carbamic acid tert-butyl ester

5 A solution of [4-(4-benzyl-piperazine-1-yl)-phenyl]-carbamic acid tert-butyl ester (43.5 g) in EtOH (1 L) containing Pd/C 10% (4 g) was hydrogenated at room temperature. After 72 hours, the catalyst was removed by filtration and the filtrate was evaporated under reduced pressure. The oily residue was then purified by flash chromatography eluting with AcOEt/isopropylamine (90/10) and the solid obtained was recrystallized from AcOEt to give the title compound (17.5 g) as white crystals.

10 m.p. : 155-157°C.

Intermediate 52(4-{4-[3-(3-Methyl-[1,2,4]oxadiazol-5-yl)-benzyl]-piperazin-1-yl}-phenyl)-carbamic acid tert-butyl ester

15 To a solution of (4-piperazin-1-yl-phenyl)-carbamic acid tert-butyl ester (2 g) in 1,2-dichloroethane (80 mL) was added 3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzaldehyde (1.4 g) and acetic acid (0.67 g). The solution was cooled at 0°C and sodium triacetoxy borohydride (3.15 g) was added portionwise and the mixture was stirred at room temperature for 16 hours. The solution was then washed with a saturated solution of NaHCO₃, with brine, dried over Na₂SO₄, filtered and evaporated under reduced pressure. The residue was purified by flash chromatography eluting with CH₂Cl₂/MeOH (98/2) to give the title compound (2.5 g) as a white solid.

20 m.p. : 159-161°C.

Intermediate 534-{4-[3-(3-Methyl-[1,2,4]oxadiazol-5-yl)-benzyl]-piperazin-1-yl}-phenylamine

30 To a stirred solution of (4-{4-[3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzyl]-piperazin-1-yl}-phenyl)-carbamic acid tert-butyl ester (2.5 g) in CH₂Cl₂ (4 mL) was added trifluoroacetic acid (6 mL) and the mixture was stirred at room temperature for 16 hours. After evaporation under reduced pressure, the residue was taken in water, basified with a 1N NaOH aqueous solution and extracted with CH₂Cl₂. The organic phase was then washed with water, dried over Na₂SO₄, filtered and evaporated. The oily residue was crystallized from MeOH/H₂O to

give the title compound (1.35 g) as a solid.

m.p. : 106-108°C.

Intermediate 54

5 3-(5-Trifluoromethyl-[1,2,4]oxadiazol-3-yl)-benzaldehyde

To a stirred solution of 3-(1,3-dioxolan-2-yl)-benzonitrile (4 g) in EtOH (130 mL) was added hydroxylamine hydrochloride (7.9 g) and potassium carbonate (15.7 g) and the mixture was refluxed for 4 hours. The hot mixture was filtered and the remaining solids were washed with EtOH and the filtrate was evaporated under reduced pressure. The crude amidoxime (4.2 g) was dissolved in trifluoroacetic acid (20 mL) and Et₃N (2 g) was added and the mixture was stirred at room temperature for 3 hours. The solution was evaporated to dryness and the residue was extracted with CH₂Cl₂. The organic phase was washed with water, dried over Na₂SO₄, filtered and evaporated. The residue was then dissolved in toluene (100 mL) and 1N aqueous hydrochloric acid (30 mL) was added and the mixture was heated at reflux for 1 hour. The mixture was cooled to room temperature, the organic phase was decanted and washed with brine, dried over Na₂SO₄, filtered and evaporated. The residue was purified by flash chromatography eluting with CH₂Cl₂ to give the title compound (2 g) as a pale yellow oil.

GCMS : m/z 242 (M⁺).

Example 1

25 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide (Method 1)

To a stirred solution of 4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenylamine (0.29 g), 4'-trifluoromethyl-biphenyl-2-carboxylic acid (0.26 g), HOBt (0.16 g), and Et₃N (0.12 g) in CH₂Cl₂ (15 mL) was added at room temperature EDCI (0.23 g) and the mixture was stirred at room temperature for 4 hours. The organic solution was then washed with water, with a saturated solution of NaHCO₃, and dried over Na₂SO₄. After filtration and evaporation of the filtrate, the residue was purified by flash chromatography eluting with CH₂Cl₂/AcOEt (90/10) and the solid obtained was recrystallized from EtOH to give the title compound (0.48 g) as white crystals.

35 m.p. : 149-150°C.

Analysis for C₃₂H₂₇F₃N₄O

Calculated :C,71.10 ; H,5.03 ; N,10.36 ;

Found : C,70.82; H,5.35; N,10.19%.

Example 25 4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide

10 To a stirred solution of 4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenylamine (150 mg), 4'-isopropyl-5-methyl-biphenyl-2-carboxylic acid (127 mg), HOBt (87 mg), and Et₃N (64 mg) in CH₂Cl₂ (10 mL) was added at room temperature EDCI (124 mg) and the mixture was stirred at room temperature for 16 hours. The organic solution was then washed with water, with a saturated solution of NaHCO₃ and dried over Na₂SO₄. After filtration and evaporation of the filtrate, the oily residue was crystallized from EtOH to give the title compound (160 mg) as white crystals.

15 m.p. : 167-169°C.

Analysis for C₃₅H₃₆N₄O

Calculated :C,79.51 ;H,6.86 ;N,10.60 ;

Found : C,79.41 ;H,6.61 ;N,10.81%.

Example 320 4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide

25 To a stirred solution of 4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenylamine (400 mg), 4'-isopropyl-6-methoxy-biphenyl-2-carboxylic acid (444 mg), HOBt (222 mg), and Et₃N (166 mg) in CH₂Cl₂ (20 mL) was added at room temperature EDCI (315 mg) and the mixture was stirred at room temperature for 16 hours. The organic solution was then washed with water, with a saturated solution of NaHCO₃ and dried over Na₂SO₄. After filtration and evaporation of the filtrate, the residue was purified by flash chromatography eluting with CH₂Cl₂/MeOH (95/5) to give the title compound (279 mg) as white crystals.

30 m.p. : 179°C.

Analysis for C₃₅H₃₆N₄O₂(0.5H₂O)

Calculated :C,75.92;H,6.73;N,10.12;

Found : C,75.65;H,6.48;N,10.35%.

Example 435 4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-

piperazin-1-yl]-phenyl]-amide

To a stirred solution of 4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenylamine (400 mg), 4'-isopropyl-6-methyl-biphenyl-2-carboxylic acid (418 mg), HOBt (222 mg), and Et₃N (166 mg) in CH₂Cl₂ (20 mL) was added at room temperature EDCI (315 mg) and the mixture was stirred at room temperature for 16 hours. The organic solution was then washed with water, with a saturated solution of NaHCO₃ and dried over Na₂SO₄. After filtration and evaporation of the filtrate, the residue was purified by flash chromatography eluting with CH₂Cl₂/MeOH (98/2) and crystallized from AcOEt to give the title compound (304 mg) as white crystals.

m.p.: 137°C.

Analysis for C₃₅H₃₆N₄O

Calculated :C,79.51 ;H,6.86 ;N,10.60 ;

Found : C,79.31 ;H,6.36 ;N,10.78%.

Example 56-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide

To a stirred solution of 4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenylamine (400 mg), 6-methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid (460 mg), HOBt (222 mg), and Et₃N (166 mg) in CH₂Cl₂ (20 mL) was added at room temperature EDCI (315 mg) and the mixture was stirred at room temperature for 16 hours. The organic solution was then washed with water, with a saturated solution of NaHCO₃ and dried over Na₂SO₄. After filtration and evaporation of the filtrate, the residue was purified by flash chromatography eluting with CH₂Cl₂/MeOH (98/2) and crystallized from AcOEt to give the title compound (122 mg) as white crystals.

m.p. : 192°C

Analysis for C₃₃H₂₉F₃N₄O

Calculated :C,71.47 ;H,5.27 ;N,10.10 ;

Found : C,71.32 ;H,5.23 ;N,10.17%.

Example 64'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid (4-{3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzyl}-piperazin-1-yl)-phenyl]-amide

To a stirred solution of (4-{4-[3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzyl]-piperazin-1-yl}-phenylamine (175 mg), 4'-isopropyl-5-methyl-biphenyl-2-

carboxylic acid (127 mg), HOBt (87 mg), and Et₃N (67 mg) in CH₂Cl₂ (20 mL) was added at room temperature EDCI (124 mg) and the mixture was stirred at room temperature for 16 hours. The organic solution was then washed with water, with a saturated solution of NaHCO₃ and dried over Na₂SO₄. After filtration and evaporation of the filtrate, the residue was purified by flash chromatography eluting with CH₂Cl₂/MeOH (98/2) and crystallized from CH₂Cl₂/diisopropyl ether to give the title compound (110 mg) as white crystals. m.p. : 145-147°C

Analysis for C₃₇H₃₉N₅O₂

Calculated : C, 75.87 ; H, 6.71 ; N, 11.96 ;
Found : C, 75.79 ; H, 7.02 ; N, 11.81%.

Similarly prepared were :

Example 7

5-Chloro-4'-isopropyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide as white crystals (280 mg), m.p. : 188-190°C

from 5-chloro-4'-isopropyl-biphenyl-2-carboxylic acid (274 mg) and 4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenylamine (292 mg).

Analysis for C₃₄H₃₃ClN₄O

Calculated : C, 74.37 ; H, 6.06 ; N, 10.20 ;
Found : C, 74.56 ; H, 6.20 ; N, 10.05%.

Example 8

6-Methoxy-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide as white crystals (225 mg), m.p. : 215-217°C

from 6-methoxy-4'-trifluoromethyl-biphenyl-2-carboxylic acid (150 mg) and 4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenylamine (150 mg).

Analysis for C₃₃H₂₉F₃N₄O₂ (0.4H₂O)

Calculated : C, 68.60 ; H, 5.20 ; N, 9.70 ;
Found : C, 68.50 ; H, 5.19 ; N, 9.56%.

Example 9

5-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide as white crystals (240 mg), m.p. : 166-168°C.

from 5-methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid (210 mg) and 4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenylamine (219 mg).

Analysis for C₃₃H₂₉F₃N₄O

Calculated :C,71.47 ;H,5.27 ;N,10.10 ;

Found : C,71.89 ;H,5.72 ;N,10.18%.

5

Example 10

5-Chloro-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide as white crystals (0.25 g),
m.p. : 164-165°C.

10


from 5-chloro-4'-trifluoromethyl-biphenyl-2-carboxylic acid (0.19 g) and 4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenylamine (0.18 g).

Analysis for C₃₂H₂₆ClF₃N₄O(0.5 H₂O) Calculated :C,65.81; H,4.66; N,9.59;













Found : C,65.49; H,4.79; N,9.75%.



15

Similarly prepared were :



Example	-Y-R ²	R ³	Molecular formula : CHN calc : CHN found : or mass spec m/z	m.p.°C
Ex 11	Ph	H	C ₃₁ H ₂₈ N ₄ O(1.2 H ₂ O) C,75.34; H,6.20; N,11.34; C,75.07; H, 5.97; N,11.24%.	169-171

Ex 12	Ph	5-OMe	C ₃₂ H ₃₀ N ₄ O ₂ C, 76.47; H, 6.02; N, 11.15 ; C, 76.71; H, 5.90; N, 10.95%.	159-161
Ex 13		4-Cl	C ₃₂ H ₂₆ ClF ₃ N ₄ O C, 66.84; H, 4.56; N, 9.74; C, 66.31; H, 4.68; N, 9.75%.	143-145
Ex 14		H	C ₃₁ H ₂₈ N ₄ O ₂ (0.5H ₂ O) C, 74.83; H, 5.87; N, 11.26; C, 74.59; H, 5.68; N, 11.63%.	133-134
Ex 15		H	C ₃₄ H ₂₉ N ₅ O ₂ (0.5H ₂ O) C, 74.43; H, 5.51; N, 12.76; C, 74.07; H, 5.36; N, 12.70%.	209-211
Ex 16		H	515(M+1)	133-135
Ex 17		5-OMe	571(M+1)	160-164
Ex18		4-Me	555(M+1)	120-124
Ex19		4-OMe	571(M+1)	151-155
Ex20		H	501(M+1)	118-122
Ex21		H	503(M+1)	124-128
Ex22		H	541(M+1)	117-121
Ex23		H	491(M+1)	200-202
Ex24		H	501(M+1)	140-144

Ex25		H	501(M+1)	72-76
Ex26		H	533(M+1)	116-120

Example 27N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-(4-trifluoromethyl-benzyloxy)-benzamide

5 To a stirred suspension of N-[4-[3-cyano-benzyl)-piperazin-1-yl]-phenyl]-2-hydroxy-benzamide (0.309 g) and K_2CO_3 (0.135 g) in acetone (10 mL) was added dropwise 4-trifluoromethyl-benzyl chloride (0.14 g) and the mixture was heated at reflux. After 16 hours, the mixture was cooled at room temperature, the salts were removed by filtration, washed with acetone and the filtrate was

10 evaporated under reduced pressure. The residue was then purified by flash chromatography eluting with $CH_2Cl_2/AcOEt$ (85/15) and the white solid obtained was recrystallized from EtOH to give the title compound (0.31 g) as white crystals.

m.p. : 190-191°C.

15 Analysis for $C_{33}H_{29}F_3N_4O_2$ Calculated : C,69.46; H,5.12 ; N,9.82 ;
 Found : C,69.49; H,5.03; N,9.80%.

Example 28N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-3-methoxy-2-(4-trifluoromethyl-benzyloxy)-benzamide

20 To a stirred suspension of N-[4-[3-cyano-benzyl)-piperazin-1-yl]-phenyl]-2-hydroxy-3-methoxy-benzamide (0.33 g) and K_2CO_3 (0.134 g) in acetone (15 mL) was added dropwise 4-trifluoromethyl-benzyl chloride (0.146 g) and the mixture was heated at reflux. After 16 hours, the mixture was cooled to room

25 temperature, the salts were removed by filtration, washed with acetone and the filtrate was evaporated under reduced pressure. The residue was then crystallized from EtOH to give the title compound (0.29 g) as pale yellow crystals.


m.p. : 118-119.5°C.

30 Analysis for $C_{34}H_{31}F_3N_4O_3$ Calculated : C,67.99; H,5.20 ; N,9.33 ;

Found : C,67.98; H,5.07; N,9.32%.

Similarly prepared were :

5



Example	Y-R ²	R ³	Molecular formula : CHN calc : CHN found :	m.p.°C
Ex 29		3-OMe	C ₃₃ H ₃₁ FN ₄ O ₃ C,71.98; H,5.67; N,10.18; C,72.50; H,5.68; N,10.06%.	118-120
Ex 30		3-OMe	C ₃₄ H ₃₄ N ₄ O ₃ C,74.70 ;H,6.27 ;N,10.25 ; C,74.73 ;H,6.37 ;N,10.10%.	140-142
Ex 31		3-OMe	C ₃₄ H ₄₀ N ₄ O ₃ C,73.88 ;H,7.29 ;N,10.14 ; C,74.30 ;H,6.91 ;N,9.97%.	102-104
Ex 32		H	C ₃₃ H ₃₈ N ₄ O ₂ C,75.83 ;H,7.33 ;N,10.72 ; C,76.34 ;H,7.19 ;N,10.52%.	119-121
Ex 33		3-OMe	C ₃₅ H ₃₆ N ₄ O ₃ C,74.98 ;H,6.47 ;N,9.99 ; C,74.57 ;H,6.42 ;N,9.70%.	134-136

10

Example 34

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide-(Method 2)

To a solution of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (0.58 g) in CH_2Cl_2 (35 mL) containing Et_3N (0.152 g) was added 3-cyano-benzyl bromide (0.267 g) and the mixture was heated at reflux for 2 hours. The solution was washed with water, dried over Na_2SO_4 , filtered and evaporated. The residue was purified by flash chromatography eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (98/2) and the solid obtained was recrystallized from $\text{MeOH}/\text{H}_2\text{O}$ to give the title compound (0.67 g) as white crystals.

m.p. : 153-155°C.

Analysis for $\text{C}_{32}\text{H}_{27}\text{F}_3\text{N}_4\text{O}$

Calculated : C, 71.10; H, 5.03; N, 10.36;

Found : C, 70.86; H, 4.98; N, 10.27%.

Example 35

N-4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-(4-fluoro-benzyloxy)-benzamide

To a solution of 2-(4-fluoro-benzyloxy)-N-(4-piperazin-1-yl-phenyl)-benzamide (0.31 g) in CH_2Cl_2 (10 mL) containing Et_3N (84 mg) was added 3-cyano-benzyl bromide (0.147 g) and the mixture was heated at reflux for 2 hours. The solution was washed with water, dried over Na_2SO_4 , filtered and evaporated. The residue was crystallized from diisopropyl ether to give the title compound (0.21 g) as white crystals.

m.p. : 114-116°C.

Analysis for $\text{C}_{32}\text{H}_{29}\text{FN}_4\text{O}_2$

C, 73.83; H, 5.61; N, 10.76;

C, 74.10; H, 5.89; N, 10.68%.

Example 36

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [3-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide

To a solution of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (3-piperazin-1-yl-phenyl)-amide (0.5 g) in acetone (20 mL) containing K_2CO_3 (0.19 g) was added 3-cyano-benzyl bromide (0.23 g) and the mixture was heated at reflux for 2 hours. The solution was cooled at room temperature and the salts were removed by filtration, washed with acetone and the filtrate was evaporated under reduced pressure. The residue was purified by crystallization from AcOEt to give the title compound (0.17 g) as white crystals.

m.p. : 170-172°C.

Analysis for C₃₂H₂₇F₃N₄O

Calculated :C,71.10; H,5.03 ; N,10.36;

Found : C,70.69; H,5.15; N,10.18%.

Example 37

5 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide

To a solution of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (0.31 g) in acetone (10 mL) containing K₂CO₃ (0.31 g) was added 2-bromo-acetamide (0.124 g) and the mixture was heated at reflux for 3 hours.

10 After cooling at room temperature the salts were removed by filtration, washed with acetone and the filtrate was evaporated under reduced pressure. The residue was purified by flash chromatography eluting with CH₂Cl₂/MeOH (95/5) and the solid obtained was recrystallized from EtOH to give the title compound (0.23 g) as white crystals.

15 m.p. : 226-228°C.

Analysis for C₂₆H₂₅F₃N₄O₂

Calculated :C,64.72 ;H,5.22 ;N,11.61 ;

Found : C,64.69 ;H,5.45 ;N,11.59%.

Example 38

20 4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide

To a solution of 4'-isopropyl-6-methoxy-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (214 mg) in acetone (20 mL) containing K₂CO₃ (206 mg) was added 2-bromo-acetamide (100 mg) and the mixture was heated at reflux for 16 hours. After cooling at room temperature the salts were removed by filtration, washed with acetone and the filtrate was evaporated under reduced pressure. The residue was purified by flash chromatography eluting with CH₂Cl₂/MeOH (92/8) and the solid obtained was recrystallized from CH₂Cl₂/diisopropyl ether to give the title compound (120 mg) as white crystals.

30 m.p. : 207-209°C

Analysis for C₂₉H₃₄N₄O₃

Calculated :C,71.58 ;H,7.04 ;N,11.51 ;

Found : C,71.68 ;H,6.47 ;N,11.44%.

Example 39

35 4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-

piperazin-1-yl)-phenyl]-amide

To a solution of 4'-isopropyl-6-methyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (206 mg) in acetone (20 mL) containing K_2CO_3 (206 mg) was added 2-bromo-acetamide (100 mg) and the mixture was heated at reflux for 16 hours. After cooling at room temperature the salts were removed by filtration, washed with acetone and the filtrate was evaporated under reduced pressure. The residue was purified by flash chromatography eluting with $CH_2Cl_2/MeOH$ (93/7) and the solid obtained was recrystallized from CH_2Cl_2 /diisopropyl ether to give the title compound (190 mg) as white crystals.

m.p. : 181-183°C

Analysis for $C_{29}H_{34}N_4O_2$

Calculated : C, 74.01 ; H, 7.28 ; N, 11.91 ;

Found : C, 73.87 ; H, 6.69 ; N, 11.84%.

Similarly prepared were :

Example 40

6-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide as white crystals (100 mg),

m.p. : 196-198°C

from 6-methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (220 mg) and 2-bromo-acetamide (100 mg).

Analysis for $C_{27}H_{27}F_3N_4O_2(0.25H_2O)$ Calculated : C, 64.73 ; H, 5.53 ; N, 11.18 ;

Found : C, 64.44 ; H, 4.93 ; N, 10.98%.

Example 41

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-cyanomethyl-piperazin-1-yl)-phenyl]-amide as white crystals (1.3 g),

m.p. : 244-246°C

from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (2.12 g) and chloro-acetonitrile (396 mg).

Analysis for $C_{26}H_{23}F_3N_4O$ ($0.25H_2O$) Calculated : C, 66.59 ; H, 5.05 ; N, 11.95 ;

Found : C, 66.51 ; H, 4.89 ; N, 11.81%.

Example 42

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-ethoxycarbonylmethyl-piperazin-1-yl)-phenyl]-amide as white crystals (5.1 g),

m.p. : 167-169°C

from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (4.25 g) and bromo-acetic acid ethyl ester (1.83 g).

Analysis for C₂₈H₂₈F₃N₃O₃

Calculated : C, 65.74 ; H, 5.52 ; N, 8.21 ;

Found : C, 65.76 ; H, 5.09 ; N, 8.16%.

Example 43

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(2-ethoxy-ethyl)-piperazin-1-yl)-phenyl]-amide as white crystals (210 mg),

m.p. : 176-178°C

from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (318 mg) and 1-bromo-2-ethoxy-ethane (126 mg).

Analysis for C₂₈H₃₀F₃N₃O₂

Calculated : C, 67.59 ; H, 6.08 ; N, 8.45 ;

Found : C, 67.63 ; H, 6.05 ; N, 8.49%.

Example 44

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-hydroxy-propyl)-piperazin-1-yl)-phenyl]-amide as white crystals (160 mg),

m.p. : 208-210°C

from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (318 mg) and 3-bromo-propan-1-ol (125 mg).

Analysis for C₂₇H₂₈F₃N₃O₂(0.5H₂O)

Calculated : C, 65.84 ; H, 5.93 ; N, 8.53 ;

Found : C, 65.66 ; H, 6.23 ; N, 8.40%.

Example 45

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(4,4,4-trifluoro-butyl)-piperazin-1-yl)-phenyl]-amide as white crystals (240 mg),

m.p. : 198-200°C

from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (297 mg) and 4-bromo-1,1,1-trifluoro-butane (143 mg).

Analysis for C₂₈H₂₇F₆N₃O (0.5H₂O)

Calculated : C, 61.76 ; H, 5.18 ; N, 7.72 ;

Found : C, 61.53 ; H, 4.88 ; N, 7.55%.

Example 46

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-methyl-but-2-enyl)-piperazin-1-yl)-phenyl]-amide as white crystals (180 mg),
m.p. : 203-205°C

5 from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (318 mg) and 1-bromo-3-methyl-but-2-ene (122 mg).

Analysis for C₂₉H₃₀F₃N₃O(0.4H₂O) Calculated : C,69.56 ;H,6.20 ;N,8.39 ;
Found : C,69.34 ;H,5.62 ;N,8.55%.

10 Example 47

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-cyano-4-fluoro-benzyl)-piperazin-1-yl)-phenyl]-amide as white crystals (440 mg),
m.p. : 168-170°C

15 from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (425 mg) and 3-cyano-4-fluoro-benzyl bromide (214 mg).

Analysis for C₃₂H₂₆F₄N₄O Calculated :C,68.81 ;H,4.69 ;N,10.03 ;
Found : C,68.83 ;H,4.55 ;N, 9.98%.

Example 48

20 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3,4-methylenedioxy-benzyl)-piperazin-1-yl)-phenyl]-amide as white crystals (180 mg),
m.p. : 189-191°C

from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (318 mg) and 3,4-methylenedioxy-benzyl chloride (140 mg).

25 Analysis for C₃₂H₂₈F₃N₃O₃ Calculated :C,68.68 ;H,5.04 ;N,7.51 ;
Found : C,68.44 ;H,5.04 ;N,7.54%.

Example 49

30 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-nitro-benzyl)-piperazin-1-yl)-phenyl]-amide as pale yellow crystals (900 mg),
m.p. : 152-154°C

from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (1.06 g) and 3-nitro-benzyl bromide (538 mg).

35 Analysis for C₃₁H₂₇F₃N₄O₃ Calculated :C,66.42 ;H,4.85 ;N,9.99 ;
Found : C,66.02 ;H,5.03 ;N,9.95%.

Example 50

4'-Trifluoromethyl-biphenyl-2-carboxylic acid (4-[4-(3-carbamoyl-benzyl)-piperazin-1-yl]-phenyl)-amide as white crystals (1.5 g),

m.p. : 199-201°C


from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (1.7 g) and 3-chloromethyl-benzamide (676 mg).

Analysis for C₃₂H₂₉F₃N₄O₂







Calculated : C, 68.81 ; H, 5.23 ; N, 10.03;

Found : C, 68.84 ; H, 5.52 ; N, 9.99%.

Similarly prepared were:



Example	-X-Z-R ¹	Molecular formula : CHN-calc : CHN found :	m.p. °C
Ex 51		C ₃₂ H ₃₀ F ₃ N ₃ O ₂ (1H ₂ O) C, 68.19; H, 5.72; N, 7.46 ; C, 68.39; H, 6.03; N, 7.07%.	168-170
Ex 52		C ₃₁ H ₂₇ F ₄ N ₃ O C, 69.78; H, 5.10; N, 7.88 ; C, 69.37; H, 5.17; N, 7.84%.	198-200
Ex 53		C ₃₁ H ₂₇ F ₄ N ₃ O(0.6H ₂ O) C, 68.40; H, 5.22; N, 7.72 ; C, 68.39; H, 5.14; N, 7.70%.	189-190.5
Ex 54		C ₃₁ H ₂₈ F ₃ N ₃ O(0.2H ₂ O) C, 71.72; H, 5.51; N, 8.09; C, 71.43; H, 5.51; N, 8.02%.	191-193

Example	-X-Z-R ¹	Molecular formula : CHN calc : CHN found :	m.p. °C
Ex 55		C33H30F3N3O3 C,69.10; H,5.27; N,7.33; C,68.70; H,5.13; N,7.10%.	190-192
Ex 56		C30H27F3N4O C,69.76; H,5.27; N,10.85; C,69.67; H,5.28; N,10.86%.	194-196
Ex 57		C30H27F3N4O(0.5H2O) C,68.56; H,5.37; N,10.66; C,68.46; H,5.21; N, 10.58%.	168-170
Ex 58		C29H26F3N5O C,67.30; H,5.06; N,13.53; C,66.84; H,5.07; N,13.30%.	183-185
Ex 59		C28H25F3N4OS(0.25H2O) C,63.80; H,4.88; N,10.63 ; C,63.69; H,4.97; N,10.65%.	187-189
Ex 60		C29H28F3N5O C,67.04; H,5.43; N,13.48 ; C,66.52; H,5.64; N, 13.28%.	118-120

Example 61

4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid (4-(4-(3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzyl)-piperazine-1-yl)-phenyl)-amide

- 5 To a solution of 4'-isopropyl-6-methyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (309 mg) in 1,2-dichloroethane (20 mL) was added 3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzaldehyde (154 mg) and acetic acid (67 mg). The solution was cooled at 0°C and sodium triacetoxy borohydride (317 mg) was added portionwise and the mixture was stirred at room temperature for 16
- 10 hours. The solution was then washed with a saturated solution of NaHCO₃, with brine, dried over Na₂SO₄, filtered and evaporated under reduced pressure. The residue was purified by flash chromatography eluting with CH₂Cl₂/MeOH (98/2) and the solid obtained was recrystallized from CH₂Cl₂/hexane to give the title

compound (140 mg) as white crystals.

m.p. : 74°C

Analysis for C₃₇H₃₉N₅O₂(0.5H₂O) Calculated : C, 74.72 ; H, 6.78 ; N, 11.78 ;
Found : C, 74.39 ; H, 6.74 ; N, 11.73%.

5

Example 62

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide

10 To a solution of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (310 mg) in 1,2-dichloroethane (20 mL) was added 1H-pyrrole-2-carboxaldehyde (95 mg) and acetic acid (67 mg). The solution was cooled at 0°C and sodium triacetoxy borohydride (317 mg) was added portionwise and the mixture was stirred at room temperature for 16 hours. The solution was then washed with a saturated solution of NaHCO₃, with brine, dried over Na₂SO₄,
15 filtered and evaporated under reduced pressure. The residue was purified by flash chromatography eluting with CH₂Cl₂/MeOH (95/5) and the solid obtained was recrystallized from EtOH to give the title compound (180 mg) as white crystals.

m.p. : 191-193°C

20 Analysis for C₂₉H₂₇F₃N₄O Calculated : C, 69.04 ; H, 5.39 ; N, 11.10 ;
Found : C, 69.56 ; H, 5.80 ; N, 11.06%.

Example 63

25 4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide

To a solution of 4'-isopropyl-5-methyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (290 mg) in 1,2-dichloroethane (20 mL) was added 1H-pyrrole-2-carboxaldehyde (68 mg) and acetic acid (67 mg). The solution was cooled at 0°C and sodium triacetoxy borohydride (317 mg) was added portionwise and
30 the mixture was stirred at room temperature for 16 hours. The solution was then washed with a saturated solution of NaHCO₃, with brine, dried over Na₂SO₄, filtered and evaporated under reduced pressure. The residue was purified by flash chromatography eluting with CH₂Cl₂/MeOH (98/2) and the solid obtained was recrystallized from MeOH to give the title compound (60 mg) as white
35 crystals.

m.p. : 185-187°C

Analysis for C₃₂H₃₆N₄O

Calculated : C, 78.02 ; H, 7.36 ; N, 11.37 ;

Found : C, 78.35 ; H, 7.11 ; N, 11.27%.

5 Example 64

5-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide

To a solution of 5-methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (329 mg) in 1,2-dichloroethane (20 mL) was added
10 1H-pyrrole-2-carboxaldehyde (86 mg) and acetic acid (54 mg). The solution was cooled at 0°C and sodium triacetoxy borohydride (238 mg) was added portionwise and the mixture was stirred at room temperature for 16 hours. The solution was then washed with a saturated solution of NaHCO₃, with brine, dried over Na₂SO₄, filtered and evaporated under reduced pressure. The residue was
15 purified by flash chromatography eluting with CH₂Cl₂/MeOH (95/5) and the oily residue obtained was crystallized from diisopropyl ether to give the title compound (210 mg) as white crystals.

m.p. : 196-198°C

Analysis for C₃₀H₂₉F₃N₄O(0.5H₂O) Calculated : C, 68.30 ; H, 5.73 ; N, 10.62 ;

20 Found : C, 68.05 ; H, 6.03 ; N, 10.36%.

Similarly prepared were :

Example 65

25 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-propyl-piperazin-1-yl)-phenyl]-amide as white crystals (160 mg),

m.p. : 207-209°C

from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (0.31 g) and propionaldehyde (64 mg).

30 Analysis for C₂₇H₂₈F₃N₃O

Calculated : C, 69.36 ; H, 6.04 ; N, 8.99 ;

Found : C, 69.47 ; H, 6.12 ; N, 8.86%.

Example 66

35 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-acetyl-benzyl)-piperazin-1-yl)-phenyl]-amide as white crystals (235 mg),

m.p.: 181-183°C.

from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (0.31 g) and 3-acetyl-benzaldehyde (122 mg).

Analysis for $C_{33}H_{30}F_3N_3O_2(0.25H_2O)$ Calculated :C,70.51 ;H,5.47 ;N,7.48 ;

Found : C,70.41 ;H,5.12 ;N,7.40%.

Example 67

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-furan-2-ylmethyl-piperazin-1-yl)-phenyl]-amide as a pale yellow solid (180 mg),

m.p. : 173-175°C

from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (0.31 g) and furan-2-carboxaldehyde (106 mg).

Analysis for $C_{29}H_{26}F_3N_3O_2$ Calculated :C,68.90 ;H,5.18 ;N,8.31 ;

Found : C,69.00 ;H,5.31 ;N,8.17%.

Example 68

4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide as white crystals (230 mg),

m.p. : 195-197°C

from 4'-isopropyl-6-methoxy-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (0.3 g) and 1H-pyrrole-2-carboxaldehyde (68.5 mg).

Analysis for $C_{32}H_{36}N_4O_2$ Calculated :C,75.56 ;H,7.13 ;N,11.01 ;

Found : C,75.79 ;H,7.16 ;N,11.03%.

Example 69

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(1-methyl-1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide as white crystals (150 mg),

m.p. : 177-179°C

from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (0.31 g) and 1-methyl-1H-pyrrole-2-carboxaldehyde (109 mg).

Analysis for $C_{30}H_{29}F_3N_4O$ (1H₂O) Calculated :C,67.15 ;H,5.82 ;N,10.44 ;

Found : C,67.45 ;H,5.70 ;N,10.51%.

Example 70

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-thiophen-2-ylmethyl-piperazin-

1-yl)-phenyl]-amide as a yellow solid (150 mg),

m.p. : 181-183°C

from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (0.31 g) and thiophene-2-carboxaldehyde (126 mg).

5 Analysis for C₂₉H₂₆F₃N₃OS (1.25H₂O) Calculated :C,64.01 ;H,5.28 ;N,7.72 ;
Found : C,64.05 ;H,5.04 ;N,7.72%.

Example 71

10 4'-Trifluoromethyl-biphenyl-2-carboxylic acid {4-[4-(1H-pyrazole-3-ylmethyl)-piperazine-1-yl]-phenyl}-amide as white crystals (210 mg),

m.p. : 194-196°C

from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (0.31 g) and 1H-pyrazole -3-carboxaldehyde (79 mg).

MS : m/z 506(M+1).

Example 72

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-thiophen-3-ylmethyl-piperazin-1-yl)-phenyl]-amide as white crystals (170 mg),

m.p. : 187-189°C

20 from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (0.31 g) and thiophene-3-carboxaldehyde (112 mg).

Analysis for C₂₉H₂₆F₃N₃OS Calculated :C,66.78 ;H,5.02 ;N,8.06 ;
Found : C,67.10 ;H,5.40 ;N,8.01%.

Example 73

4'-Trifluoromethyl-biphenyl-2-carboxylic acid {4-[4-(5-fluoro-1H-indol-3-ylmethyl)-piperazin-1-yl]-phenyl}-amide as white crystals (190 mg),

m.p. : 168-170°C

30 from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (318 mg) and 5-fluoro-1H-indole-3-carboxaldehyde (135 mg).

Analysis for C₃₃H₂₈F₄N₄O (0.5H₂O) Calculated :C,68.15 ;H,5.03 ;N,9.63 ;
Found : C,67.97 ;H,5.09 ;N,9.43%.

Example 74

4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid (4-(4-(3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzyl)-piperazine-1-yl)-phenyl)-amide as white crystals (300 mg),

m.p. : 180-182°C

5 from 4'-isopropyl-6-methoxy-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (0.32 g) and 3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzaldehyde (154 mg).

Analysis for C₃₇H₃₉N₅O₃(0.5H₂O) Calculated :C,72.76 ;H,6.60 ;N,11.47 ;

Found : C,72.80 ;H,6.59 ;N,11.31%.

10

Example 75

4'-Trifluoromethyl-biphenyl-2-carboxylic acid (4-(4-[3-(5-trifluoromethyl-[1,2,4]oxadiazol-3-yl)-benzyl]-piperazin-1-yl)-phenyl)-amide as white crystals (240 mg),

15 m.p. : 188-190°C

from 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (0.31 g) and 3-(5-trifluoromethyl-[1,2,4]oxadiazol-3-yl)-benzaldehyde (198 mg).

Analysis for C₃₄H₂₇F₆N₅O₂ Calculated :C,62.67 ;H,4.18 ;N,10.75 ;

20 Found : C,62.09 ;H,4.65 ;N,10.56%.

Example 76

(4-(4-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl)-piperazin-1-yl)-acetic acid

25 To a solution of 4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-ethoxycarbonylmethyl-piperazin-1-yl)-phenyl]-amide (4.6 g) in EtOH (80 mL) was added 1N sodium hydroxide and the mixture was stirred under reflux for 2 hours. The solution was cooled at room temperature, acidified with concentrated HCl and evaporated to dryness. The solid residue was purified by flash
30 chromatography eluting with CH₂Cl₂/MeOH/Et₃N (70/30/0.2) and the solid was recrystallized from EtOH to give the title compound (4.2 g) as white crystals.
m.p.: 195-197°C.

Example 77

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-[(biphenyl-3-ylmethyl)-carbamoyl]-methyl)-piperazin-1-yl]-phenyl]-amide

To a stirred solution of (4-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazin-1-yl)-acetic acid (241 mg), biphenyl-3-yl-methylamine (95 mg),
5 HOBt (87 mg), and Et₃N (202 mg) in CH₂Cl₂ (20 mL) was added EDCI (125 mg) and the mixture was stirred at room temperature for 16 hours. The organic solution was then washed with water, with a saturated solution of NaHCO₃ and dried over Na₂SO₄. After filtration and evaporation of the filtrate, the residue was purified by flash chromatography eluting with CH₂Cl₂/MeOH (97/3) and the solid
10 obtained was recrystallized from EtOH to give the title compound (180 mg) as white crystals.

m.p.: 165-167°C.

Analysis for C₃₉H₃₅F₃N₄O₂

Calculated :C,72.21 ;H,5.44 ;N,8.64;

Found : C,71.94 ;H,5.66 ;N,8.53%.

Example 78

3-(4-{4-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazin-1-ylmethyl)-benzoic acid

To a solution of 4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-{4-(3-carbomethoxy-benzyl)-piperazin-1-yl]-phenyl]-amide (1.6 g) in EtOH (100 mL)
20 was added 1N sodium hydroxide (5.6 mL) and the mixture was stirred under reflux for 16 hours. The solution was cooled at room temperature and acidified with 1N hydrochloric acid (5.6 mL). The white precipitate obtained was filtered and recrystallized from EtOH to give the title compound (1.4 g) as white crystals.

25 m.p.: 225-227°C.

Example 79

4'-Trifluoromethyl-biphenyl-2-carboxylic acid (4-{4-[3-(2,2,2-trifluoro-ethylcarbamoyl)-benzyl]-piperazin-1-yl}-phenyl)-amide

To a stirred solution of 3-(4-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazin-1-ylmethyl)-benzoic acid (279 mg), 2,2,2-trifluoro-ethylamine (74 mg), HOBt (85 mg), and Et₃N (63 mg) in CH₂Cl₂ (10 mL) was added EDCI
30 (125 mg) and the mixture was stirred at room temperature for 48 hours. The organic solution was then washed with water, with a saturated solution of NaHCO₃ and dried over Na₂SO₄. After filtration and evaporation of the filtrate,
35

the residue was purified by flash chromatography eluting with $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (97/3) and the solid obtained was recrystallized from CH_2Cl_2 /diisopropyl ether to give the title compound (190 mg) as white crystals.

m.p.: 205-207°C.

5 Analysis for $\text{C}_{34}\text{H}_{30}\text{F}_6\text{N}_4\text{O}_2$ Calculated : C,63.75; H,4.72; N,8.75;
Found : C,63.65; H,4.95; N,8.63%.

Example 80

10 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzoyl)-piperazin-1-yl]-phenyl]-amide

To a stirred solution of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (0.318 g) in CH_2Cl_2 (15 mL) containing Et_3N (79 mg) was added dropwise 3-cyano-benzoyl chloride (0.129 g) and the mixture was stirred at room temperature for 1 hour. The solution was then washed with water, with
15 brine, dried over Na_2SO_4 , filtered and evaporated. The residue was then purified by flash chromatography eluting with $\text{CH}_2\text{Cl}_2/\text{AcOEt}$ (80/20) and the solid obtained was recrystallized from AcOEt to give the title compound (0.29 g) as white crystals.

m.p. : 178.5-180°C.

20 Analysis for $\text{C}_{32}\text{H}_{25}\text{F}_3\text{N}_4\text{O}_2$ Calculated : C,69.31; H,4.54; N,10.10;
Found : C,69.49; H,4.63; N,10.08%.

Example 81

25 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-acetyl-piperazin-1-yl)-phenyl]-amide

A solution of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (212 mg) in acetic anhydride (10 mL) was stirred at room temperature for 16 hours. The solution was evaporated under reduced pressure, and the residue was dissolved in CH_2Cl_2 and washed with a saturated solution of
30 NaHCO_3 , with brine, dried over Na_2SO_4 , filtered and evaporated. The oily residue was crystallized from AcOEt to give the title compound (130 mg) as white crystals.

m.p. : 175-176.5°C

35 Analysis for $\text{C}_{26}\text{H}_{24}\text{F}_3\text{N}_3\text{O}_2$ Calculated : C,66.80 ; H,5.17 ; N,8.99;
Found : C,66.69 ; H,5.15 ; N,8.87%.

Example 824'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzenesulfonyl)-piperazin-1-yl]-phenyl]-amide

5 To a stirred solution of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (0.318 g) in CH_2Cl_2 (20 mL) containing Et_3N (90 mg) was added dropwise 3-cyano-benzenesulfonyl chloride (0.179 g) and the mixture was stirred at room temperature for 48 hours. The solution was then washed with water, with brine, dried over Na_2SO_4 , filtered and evaporated. The residue
10 was then purified by flash chromatography eluting with CH_2Cl_2 to give the title compound (0.39 g) as a white solid.

m.p. : 223°C.

Analysis for $\text{C}_{31}\text{H}_{25}\text{F}_3\text{N}_4\text{O}_3\text{S}(0.5\text{H}_2\text{O})$ Calculated :C,62.10; H,4.37; N,9.34;

Found : C,62.03; H,4.55; N,9.11%.

Example 834'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-methanesulfonyl-piperazin-1-yl)-phenyl]-amide

To a solution of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperazin-1-yl-phenyl)-amide (318 mg) in CH_2Cl_2 (10 mL) containing Et_3N (91 mg) was added
20 methanesulfonyl chloride (70 μL) and the mixture was stirred at room temperature for 1 hour. The solution was washed with water, with brine and dried over Na_2SO_4 , filtered and evaporated. The solid obtained was recrystallized from CH_3CN to give the title compound (170 mg) as white crystals.

25 m.p. : 254-256°C.

Analysis for $\text{C}_{25}\text{H}_{24}\text{F}_3\text{N}_3\text{O}_3\text{S}$

Calculated :C,59.63 ;H,4.80 ;N,8.34 ;

Found : C,59.58 ;H,5.10 ;N,8.57%.

Example 84

30 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[1-(3-cyano-benzyl)-piperidin-4-yl]-phenyl]-amide

To a solution of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (4-piperidin-4-yl-phenyl)-amide trifluoroacetate salt (0.23 g) in acetone (10 mL) containing K_2CO_3 (0.18 g) was added 3-cyano-benzyl bromide (0.086 g) and the mixture was
35 heated at reflux. After 16 hours, the mixture was cooled at room temperature,

the salts were removed by filtration, washed with acetone and the filtrate was evaporated under reduced pressure. The residue was purified by flash chromatography eluting with CH₂Cl₂/MeOH (98/2) and the oily residue was crystallized from diisopropyl ether to give the title compound (0.13 g) as white crystals.

m.p. : 124-126°C.

Analysis for C₃₃H₂₈F₃N₃O

Calculated : C,73.45 ;H,5.23 ;N,7.79 ;

Found : C,73.43 ;H,5.56 ;N,7.91%.

10 Example 85

N-{4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl}-2-pyrrol-1-yl-benzamide as a pale yellow solid (426 mg),

m.p. : 174°C

from 2-pyrrol-1-yl-benzoic acid (538 mg) and 4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenylamine (700 mg).

15 Analysis for C₂₉H₂₇N₅O

Calculated : C,75.46 ;H,5.90 ;N,15.17 ;

Found : C,75.09 ;H,6.07 ;N,15.15%.

Example 86

20 N-{4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl}-2-pyridin-2-yl-benzamide as white crystals (200 mg),

m.p. : 169-171°C

from 2-pyridin-2-yl-benzoic acid (199 mg) and 4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenylamine (292 mg).

25 Analysis for C₃₀H₂₇N₅O

Calculated : C,76.09 ;H,5.75 ;N,14.79 ;

Found : C,76.04 ;H,5.94 ;N,14.47%.

Example 87

30 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide citrate salt

To a solution of 4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide (0.2 g) in MeOH (15 mL) was added citric acid (71 mg) and the resulting solution was stirred at room temperature. The solution was then evaporated to dryness and the solid was triturated in Et₂O, filtered and dried to give the title compound (0.15 g) as a white powder.

m.p. : 120°C.

Example 88

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide hydrochloride salt

To a solution of 4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide (0.2 g) in AcOEt (25 mL) was added 1N hydrochloric acid (0.9 mL) and the resulting solution was stirred at room temperature for 1.5 hours. The solution was then evaporated to dryness and the solid was recrystallized from AcOEt/hexane to give the title compound (0.18 g) as a white powder.

m.p. : 165°C.

Biological Assay

Primary human hepatocytes were seeded at 50 000 cells/well in 96 well plates. After an overnight adhesion phase, cells were incubated with compounds for 8 hours in RPMI medium containing 1% FCS, 4 µg/ml insulin, 100 nM dexamethasone and 50 µCi/ml ³⁵S-methionine. Compounds were dissolved in DMSO and tested onto cells from 1 µM to 1.6 nM. Production of radiolabeled apoB-100 and apoA-1 (used as a selectivity-control) was quantified by analysis of supernatants using SDS PAGE and exposure of gels onto PhosphorImager screens. Inhibition of apoB-100 and apoA-1 secretion by compounds was calculated taking untreated cells as controls, and IC₅₀ of each compound was determined on both apoproteins. The following results were obtained for a selection of compounds of the invention:

Example no.	Primary human hepatocytes IC ₅₀ (nM)
1	13
3	18
63	20
4	12
3	13
62	10

2	18
6	18
64	19
5	15

Tablet compositions

The following compositions A and B can be prepared by wet granulation of ingredients (a) to (c) and (a) to (d) with a solution of povidone, followed by addition of the magnesium stearate and compression.

Composition A

		<u>mg/tablet</u>	<u>mg/tablet</u>
(a)	Active ingredient	250	250
(b)	Lactose B.P.	210	26
(c)	Sodium Starch Glycollate	20	12
(d)	Povidone B.P.	15	9
(e)	Magnesium Stearate	<u>5</u>	<u>3</u>
		500	300

Composition-B

		<u>mg/tablet</u>	<u>mg/tablet</u>
(a)	Active ingredient	250	250
(b)	Lactose 150	150	-
(c)	Avicel PH 101	60	26
(d)	Sodium Starch Glycollate	20	12
(e)	Povidone B.P.	15	9
(f)	Magnesium Stearate	<u>5</u>	<u>3</u>
		500	300

Composition C

	<u>mg/tablet</u>
Active ingredient	100
Lactose	200
Starch	50
Povidone	5

69

Magnesium Stearate

4
359

5 The following compositions D and E can be prepared by direct compression of the admixed ingredients. The lactose used in composition E is of the direct compression type.

Composition D

	<u>mg/tablet</u>
10 Active ingredient	250
Magnesium Stearate	4
Pregelatinised Starch NF15	<u>146</u>
	400

15 Composition E

	<u>mg/tablet</u>
Active ingredient	250
Magnesium Stearate	5
Lactose	145
20 Avicel	<u>100</u>
	500

Composition F (Controlled release composition)

	<u>mg/tablet</u>
25 (a) Active ingredient	500
(b) Hydroxypropylmethylcellulose (Methocel K4M Premium)	112
(c) Lactose B.P.	53
(d) Povidone B.P.C.	28
30 (e) Magnesium Stearate	<u>7</u>
	700

35 The composition can be prepared by wet granulation of ingredients (a) to (c) with a solution of povidone, followed by addition of the magnesium stearate and compression.

Composition G (Enteric-coated tablet)

Enteric-coated tablets of Composition C can be prepared by coating the tablets with 25mg/tablet of an enteric polymer such as cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethyl- cellulose phthalate, or anionic polymers of methacrylic acid and methacrylic acid methyl ester (Eudragit L). Except for Eudragit L, these polymers should also include 10% (by weight of the quantity of polymer used) of a plasticizer to prevent membrane cracking during application or on storage. Suitable plasticizers include diethyl phthalate, tributyl citrate and triacetin.

Composition H (Enteric-coated controlled release tablet)

Enteric-coated tablets of Composition F can be prepared by coating the tablets with 50mg/tablet of an enteric polymer such as cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethyl- cellulose phthalate, or anionic polymers of methacrylic acid and methacrylic acid methyl ester (Eudragit L). Except for Eudragit L, these polymers should also include 10% (by weight of the quantity of polymer used) of a plasticizer to prevent membrane cracking during application or on storage. Suitable plasticizers include diethyl phthalate, tributyl citrate and triacetin.

(ii) Capsule compositionsComposition A

Capsules can be prepared by admixing the ingredients of Composition D above and filling two-part hard gelatin capsules with the resulting mixture. Composition B (infra) may be prepared in a similar manner.

Composition B

		<u>mg/capsule</u>
(a)	Active ingredient	250
(b)	Lactose B.P.	143
(c)	Sodium Starch Glycollate	25
(d)	Magnesium Stearate	<u>2</u>
		420

Composition C

	<u>mg/capsule</u>
(a) Active ingredient	250
(b) Macrogol 4000 BP	<u>350</u>
	600

Capsules can be prepared by melting the Macrogol 4000 BP, dispersing the active ingredient in the melt and filling two-part hard gelatin capsules therewith.

Composition D

	<u>mg/capsule</u>
Active ingredient	250
Lecithin	100
Arachis Oil	<u>100</u>
	450

Capsules can be prepared by dispersing the active ingredient in the lecithin and arachis oil and filling soft, elastic gelatin capsules with the dispersion.

Composition E (Controlled release capsule)

	<u>mg/capsule</u>
(a) Active ingredient	250
(b) Microcrystalline Cellulose	125
(c) Lactose BP	125
(d) Ethyl Cellulose	<u>13</u>
	513

The controlled release capsule composition can be prepared by extruding mixed ingredients (a) to (c) using an extruder, then spheronising and drying the extrudate. The dried pellets are coated with a release controlling membrane (d) and filled into two-part, hard gelatin capsules.

Composition F (Enteric capsule)

	<u>mg/capsule</u>
(a) Active ingredient	250

(b)	Microcrystalline Cellulose	125
(c)	Lactose BP	125
(d)	Cellulose Acetate Phthalate	50
(e)	Diethyl Phthalate	<u>5</u>
		555

The enteric capsule composition can be prepared by extruding mixed ingredients (a) to (c) using an extruder, then spheronising and drying the extrudate. The dried pellets are coated with an enteric membrane (d) containing a plasticizer (e) and filled into two-part, hard gelatin capsules.

Composition G (Enteric-coated controlled release capsule)

Enteric capsules of Composition E can be prepared by coating the controlled-release pellets with 50mg/capsule of an enteric polymer such as cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropylmethylcellulose phthalate, or anionic polymers of methacrylic acid and methacrylic acid methyl ester (Eudragit L). Except for Eudragit L, these polymers should also include 10% (by weight of the quantity of polymer used) of a plasticizer to prevent membrane cracking during application or on storage. Suitable plasticizers include diethyl phthalate, tributyl citrate and triacetin.

(iii) Intravenous injection composition

Active ingredient	0.200g
Sterile, pyrogen-free phosphate buffer (pH 9.0) to	10 ml

The active ingredient is dissolved in most of the phosphate buffer at 35-40°C, then made up to volume and filtered through a sterile micropore filter into sterile 10 ml glass vials (Type 1) which are sealed with sterile closures and overseals.

(iv) Intramuscular injection composition

Active ingredient	0.20 g
Benzyl Alcohol	0.10 g
Glycofurol 75	1.45 g
Water for Injection q.s. to	3.00 ml

The active ingredient is dissolved in the glycofurool. The benzyl alcohol is then added and dissolved, and water added to 3 ml. The mixture is then filtered through a sterile micropore filter and sealed in sterile 3 ml glass vials (Type 1).

5

(v) Syrup composition

	Active ingredient	0.25g
	Sorbitol Solution	1.50g
10	Glycerol	1.00g
	Sodium Benzoate	0.005g
	Flavour	0.0125ml
	Purified Water q.s. to	5.0ml

15 The sodium benzoate is dissolved in a portion of the purified water and the sorbitol solution added. The active ingredient is added and dissolved. The resulting solution is mixed with the glycerol and then made up to the required volume with the purified water.

20 ~~(vi) Suppository composition~~

		<u>mg/suppository</u>
	Active ingredient	250
	Hard Fat, BP (Witepsol H15 - Dynamit NoBel)	<u>1770</u>
25		2020

30 One-fifth of the Witepsol H15 is melted in a steam-jacketed pan at 45°C maximum. The active ingredient is sifted through a 200µm sieve and added to the molten base with mixing, using a Silverson fitted with a cutting head, until a smooth dispersion is achieved. Maintaining the mixture at 45°C, the remaining Witepsol H15 is added to the suspension which is stirred to ensure a homogenous mix. The entire suspension is then passed through a 250µm stainless steel screen and, with continuous stirring, allowed to cool to 40°C. At a temperature of 38-40°C, 2.02g aliquots of the mixture are filled into suitable plastic moulds and the suppositories allowed to cool to room temperature.

35

(vii) Pessary composition

	<u>mg/pessary</u>
Active ingredient (63lm)	250
5 Anhydrous Dextrose	380
Potato Starch	363
Magnesium Stearate	<u>7</u>
	1000

- 10 The above ingredients are mixed directly and pessaries prepared by compression of the resulting mixture.


(viii) Transdermal composition

15 Active ingredient	200mg
Alcohol USP	0.1ml
Hydroxyethyl cellulose	

- 20 The active ingredient and alcohol USP are gelled with hydroxyethyl cellulose and packed in a transdermal device with a surface area of 10 cm².

Claims

1. A compound of formula (I)



wherein

A represents N or CH;

X is selected from the following groups:

(i) $-C_{1-6}$ alkylene-, optionally containing one or two double bonds and optionally substituted by one or more hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} acyl or C_{1-6} acyloxy groups,

(ii) oxo, sulfonyl, thioxo,

(iii) $-C_{1-6}$ alkylenecarbonyl-, $-C_{1-6}$ alkylenesulfonyl-, $-C_{1-6}$ alkylenethioxo-,

(iv) $-C_{2-6}$ alkyleneoxy-, $-C_{2-6}$ alkylenethio-, $-C_{2-6}$ alkylene(N-H or N- C_{1-6} alkyl)amino-,

(v) $-C_{1-6}$ alkylenecarboxy-, $-C_{1-6}$ alkylenethioamido-, $-C_{1-6}$ alkylene(N-H or N- C_{1-6} alkyl)carboxamido-, and

(vi) $-C_{2-6}$ alkyleneoxycarbonyl-, $-C_{2-6}$ alkylenethiocarbonyl-, $-C_{2-6}$ alkylene(N-H or N- C_{1-6} alkyl)aminocarbonyl-;

Z represents a direct link or $-C_{1-6}$ alkylene-, optionally containing one double bond and optionally substituted by one or more hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} acyl or C_{1-6} acyloxy groups ;

R^1 is selected from the following groups:

(i) hydrogen, C_{1-3} perfluoroalkyl,

(ii) C_{6-10} aryl, C_{3-8} cycloalkyl and fused benz derivatives

thereof,

- C₇₋₁₀polycycloalkyl, C₄₋₆cycloalkenyl, C₇₋₁₀polycycloalkenyl,
- (iii) a heterocyclyl selected from the group consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of from 5-14 ring atoms, wherein said radicals contain a total of from 1-4 ring heteroatoms independently selected from oxygen, nitrogen and sulfur, and wherein individual rings of said radicals may be independently saturated, partially unsaturated, or aromatic, and
- (iv) where either X is C₁₋₆alkylene and Z is a direct link, or Z is C₁₋₆alkylene, R¹ additionally may represent a halogen, cyano, nitro or C₁₋₆acyl group,

wherein, when R¹ contains one or more rings, said rings may each independently bear 0 to 4 substituents independently selected from

- (i) halogen, hydroxy, cyano, nitro, formyl, C₁₋₆alkylsulfonylamino,
- (ii) C₁₋₆alkyl, C₃₋₈cycloalkyl, C₁₋₃perfluoroalkyl,
- (iii) C₁₋₆alkoxy, methylenedioxy, C₁₋₃perfluoroalkoxy, C₁₋₆alkylthio,
- (iv) amino, C₁₋₆alkylamino, di-C₁₋₆alkylamino,
- (v) phenyl, phenoxy, phenylthio, halophenylthio, benzyl, benzyloxy,
- (vi) hydroxycarbonyl, C₁₋₆alkoxycarbonyl,
- (vii) aminocarbonyl, C₁₋₆alkylaminocarbonyl, di-C₁₋₆alkylaminocarbonyl, di-C₁₋₆alkylaminocarbonylC₁₋₆alkoxy, C₁₋₃perfluoroalkylaminocarbonyl,
- (viii) C₁₋₆acyl, C₁₋₆acyloxy, C₁₋₆acyloxyC₁₋₆alkyl, C₁₋₆acylamino, and
- (ix) an aromatic heterocyclyl consisting of monocyclic radicals, wherein said radicals contain 5-6 ring atoms, wherein said radicals contain a total of from 1-4 ring heteroatoms independently selected from oxygen, nitrogen and sulfur, and where each of the said heterocyclyl groups is optionally substituted by one or more groups independently selected from halogen, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₃perfluoroalkyl and C₁₋₃perfluoroalkoxy;

Y represents a direct or oxy link, -C₁₋₆alkylene-, -oxyC₁₋₆alkylene- or a heterocyclyl consisting of monocyclic radicals, wherein said radicals contain 5 ring atoms, and wherein said radicals contain a total of from 1-4 ring heteroatoms independently selected from oxygen, nitrogen and sulfur and wherein the ring may be independently saturated, partially unsaturated, or aromatic;

R² represents phenyl, C₃₋₈cycloalkyl, or a heterocyclyl consisting of monocyclic radicals, wherein said radicals contain a total of from 5-6 ring atoms, wherein said radicals contain a total of from 1-4 ring heteroatoms independently selected from oxygen, nitrogen and sulfur, wherein the ring may be independently saturated, partially unsaturated, or aromatic, and where each R² is optionally substituted by one or more groups independently selected from halogen, C₁₋₄alkyl, C₁₋₄alkoxy, C₃₋₈cycloalkyl, C₁₋₃perfluoroalkyl, C₁₋₃perfluoroalkoxy, hydroxycarbonyl, C₁₋₆alkoxycarbonyl, cyano, nitro, C₁₋₄alkylaminosulfonyl;

R³ represents hydrogen or one or more groups independently selected from halogen, C₁₋₄alkyl, C₁₋₄alkoxy, C₁₋₃ perfluoroalkyl or C₁₋₃ perfluoroalkoxy; or a physiologically acceptable salt, solvate or derivative thereof.

2. A compound according to claim 1 where A represents N and the piperazine group is para substituted.

3. A compound according to claim 1 or 2 where X is -C₁₋₆alkylene-, optionally containing by one double bond, oxo, sulfonyl, -C₂₋₅alkyleneoxy-, -C₁₋₄alkylenecarboxy- or -C₁₋₄alkylene(N-H or N-C₁₋₆alkyl)carboxamido-.

4. A compound according to claim 1 or 2 where X is methylene, oxo, or sulfonyl.

5. A compound according to claim 1 or 2 where X is a methylene group.

6. A compound according to any one of claims 1 to 5 where Z is a direct link or C₁₋₆alkylene.

7. A compound according to any one of claims 1 to 6 where X is a methylene group and Z is a direct link.

8. A compound according to any one of claims 1 to 7 where R¹ is selected from the following groups

(i) hydrogen, cyano, C₁₋₃perfluoroalkyl,

- (ii) optionally substituted phenyl, where optional substitution is effected by one or two groups independently selected from C₁₋₆ alkyl, cyano, halogen, C₁₋₆alkoxy, C₁₋₃perfluoroalkyl, hydroxycarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyl, methylenedioxy, nitro, C₁₋₆ acyl, phenyl, or an optionally substituted aromatic heterocyclyl consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of 5 ring atoms, where optional substitution is effected by C₁₋₄ alkyl, or C₁₋₃perfluoroalkyl, or
- (iii) an optionally substituted aromatic heterocyclyl consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of from 5-10 ring atoms, where optional substitution is effected by C₁₋₄ alkyl, or C₁₋₃perfluoroalkyl.
9. A compound according to any one of claims 1 to 9 where R¹ is an optionally substituted oxadiazolyl or pyrrolyl, where optional substitution is effected by a methyl group.
10. A compound according to any one of claims 1 to 8 where R¹ selected from the following groups
- (i) hydrogen,
 - (ii) substituted phenyl, where substitution is effected by cyano or a methyl substituted oxadiazolyl group, or
 - (iii) a pyrrolyl group.
11. A compound according to any one of claims 1-8 where X-Z is methylene or oxo and R¹ is phenyl or a heterocyclyl, where each R¹ is optionally substituted by one or more groups independently selected from C₁₋₆ alkyl, cyano, halogen, C₁₋₆alkoxy, trifluoromethyl, hydroxycarbonyl and C₁₋₄alkoxycarbonyl.
12. A compound according to any one of claims 1-8 where R¹ is phenyl substituted by 3-cyano.
13. A compound according to claim 1 where -X-Z-R¹ is aminocarbonylmethyl, pyrrolylmethyl, or phenylmethyl substituted by cyano or methyl-oxadiazole.

14. A compound according to any one of claims 1-13 where Y is a direct link, a 2,5-substituted oxazolyl group, or $-(CH_2)_n-O-$, where n is an integer from 0-3.


15. A compound according to any one of claims 1-14 where Y is a direct link.

16. A compound according to any one of claims 1-15 where R^2 is cyclohexyl, a 5-6 membered aromatic heterocyclyl or a phenyl group optionally substituted by one or two groups independently selected from halogen, C_{1-4} alkyl, C_{1-4} alkoxy or trifluoromethyl groups, where substitution is suitably in one or two of the 2-, 3-, or 4- positions on the phenyl ring.

17. A compound according to any one of claims 1-16 where Y is a direct link and R^2 is a phenyl group substituted by a trifluoromethyl or isopropyl group in the 4-position.

18. A compound according to any one of claims 1-17 where R^3 is hydrogen, halogen, C_{1-4} alkyl or C_{1-4} alkoxy.

19. A compound according claim 1 represented by formula (Ia)



wherein

A is CH or N;

X is suitably C_{1-6} alkylene, optionally containing by one double bond, oxo, sulfonyl, $-C_{2-6}$ alkyleneoxy-, $-C_{1-6}$ alkylencarboxy- or $-C_{1-6}$ alkylene(N-H or N- C_{1-6} alkyl)carboxamido;

Z represents a direct link or C_{1-6} alkylene ;

R^1 represents one of the following groups

(i) hydrogen, C_{1-3} perfluoroalkyl,

(ii) optionally substituted phenyl, where optional substitution is effected by one or two groups independently selected from C_{1-6} alkyl, cyano, halogen,


- C_{1-6} alkoxy, C_{1-3} perfluoroalkyl, hydroxycarbonyl, C_{1-4} alkoxycarbonyl, aminocarbonyl, C_{1-3} perfluoroalkylaminocarbonyl, methylenedioxy, nitro, C_{1-6} acyl, phenyl, or an optionally substituted aromatic heterocycyl consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of 5 ring atoms, where optional substitution is effected by C_{1-4} alkyl, or C_{1-3} perfluoroalkyl,
- (iii) an optionally substituted aromatic heterocycyl consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of from 5-10 ring atoms, where optional substitution is effected by C_{1-4} alkyl, or C_{1-3} perfluoroalkyl; or
- (iv) where either X is C_{1-6} alkylene and Z is a direct link, or Z is C_{1-6} alkylene, R^1 additionally may represent a cyano group;

Y represents a direct or oxy link, a 5-membered aromatic heterocycyl, $-C_{1-6}$ alkylene- or $-oxyC_{1-6}$ alkylene-;

R^2 represents phenyl, C_{3-6} cycloalkyl, or an aromatic hetrocycle containing 5-6 ring atoms and 1-4 ring heteroatoms, where each ring is optionally substituted by one or more groups independently selected from halogen, C_{1-4} alkyl, C_{1-4} alkoxy or C_{1-3} perfluoroalkyl;

R^3 represents hydrogen, halogen, C_{1-4} alkyl or C_{1-4} alkoxy; or a physiologically acceptable salt, solvate or derivative thereof.

20. A compound according to claim 1 represented by a compound of formula (Ie)



wherein
 R^1 is selected from the following groups

- (i) aminocarbonyl,
- (ii) phenyl, optionally substituted by C₁₋₆ alkyl, cyano, halogen, C₁₋₆alkoxy, C₁₋₃perfluoroalkyl, hydroxycarbonyl, C₁₋₄alkoxycarbonyl, aminocarbonyl, methylenedioxy, nitro, C₁₋₆ acyl, phenyl, or an optionally substituted 5-membered aromatic heterocyclyl, where optional substitution is effected by C₁₋₄ alkyl or C₁₋₃perfluoroalkyl, or
- (iii) an optionally substituted aromatic heterocyclyl consisting of monocyclic radicals and fused polycyclic radicals, wherein said radicals contain a total of from 5-10 ring atoms, where optional substitution is effected by C₁₋₄ alkyl;

R² represents phenyl, optionally substituted by one or two groups independently selected from halogen, C₁₋₃perfluoroalkyl, C₁₋₄alkyl and C₁₋₄alkoxy groups;

R³ represents hydrogen, halogen, C₁₋₄alkyl or C₁₋₄alkoxy;

or a physiologically acceptable salt, solvate or derivative thereof.

21. A compound selected from the group consisting of:

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

6-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid (4-{3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzyl}-piperazin-1-yl)-phenyl)-amide ;

5-Chloro-4'-isopropyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

6-Methoxy-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

5-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

- 5-Chloro-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;
Biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
5-Methoxy-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
5 4-Chloro-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-phenoxy-benzamide;
N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-(5-phenyl-oxazol-2-yl)-benzamide;
10 4'-Isopropyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
5-Methoxy-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
15 4-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
4-Methoxy-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
4'-Ethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
20 4'-Methoxy-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
3'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
25 4'-Fluoro-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
3',4'-Dimethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
2',4'-Dimethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
30 3',4'-Dimethoxy-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide;
N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-(4-trifluoromethyl-benzyloxy)-benzamide ;
35 N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-3-methoxy-2-(4-trifluoromethyl-

- benzyloxy)-benzamide ;
- N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-(4-fluoro-benzyloxy)-3-methoxy-benzamide ;
- 5 N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-3-methoxy-2-phenethyloxy-benzamide ;
- N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-(2-cyclohexyl-ethoxy)-3-methoxy-benzamide ;
- N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-(2-cyclohexyl-ethoxy)-benzamide ;
- 10 N-[4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-3-methoxy-2-(3-phenyl-propoxy)-benzamide ;
- N-4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl]-2-(4-fluoro-benzyloxy)-benzamide ;
- 15 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [3-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 20 4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 6-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-cyanomethyl-piperazin-1-yl)-phenyl]-amide ;
- 25 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-ethoxycarbonylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(2-ethoxy-ethyl)-piperazin-1-yl)-phenyl]-amide ;
- 30 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-hydroxy-propyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(4,4,4-trifluoro-butyl)-piperazin-1-yl)-phenyl]-amide ;
- 35 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-methyl-but-2-enyl)-piperazin-1-yl)-phenyl]-amide ;

- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-cyano-4-fluoro-benzyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3,4-methylenedioxy-benzyl)-piperazin-1-yl)-phenyl]-amide ;
- 5 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-nitro-benzyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-carbamoyl-benzyl)-piperazin-1-yl]-phenyl]-amide ;
- 10 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-methoxy-benzyl)-piperazin-1-yl]-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(4-fluoro-benzyl)-piperazin-1-yl]-phenyl]-amide;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-fluoro-benzyl)-piperazin-1-yl]-phenyl]-amide;
- 15 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-benzyl)-piperazin-1-yl]-phenyl]-amide;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-carbomethoxy-benzyl)-piperazin-1-yl]-phenyl]-amide;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-pyridin-4-ylmethyl-piperazin-1-yl)-phenyl]-amide;
- 20 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-pyridin-2-ylmethyl-piperazin-1-yl)-phenyl]-amide;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-pyrazin-2-ylmethyl-piperazin-1-yl)-phenyl]-amide;
- 25 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-thiazol-2-ylmethyl-piperazin-1-yl)-phenyl]-amide;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(1-methyl-1H-imidazol-2-ylmethyl)-piperazin-1-yl]-phenyl]-amide;
- 4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid (4-(4-(3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzyl)-piperazine-1-yl)-phenyl)-amide ;
- 30 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide ;
- 35 5-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-

- ylmethyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-propyl-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(3-acetyl-benzyl)-piperazin-1-yl)-phenyl]-amide ;
- 5 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-furan-2-ylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide ;
- 10 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(1-methyl-1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-thiophen-2-ylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid {4-[4-(1H-pyrazole-3-ylmethyl)-piperazine-1-yl]-phenyl}-amide ;
- 15 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-thiophen-3-ylmethyl-piperazin-1-yl)-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid {4-[4-(5-fluoro-1H-indol-3-ylmethyl)-piperazin-1-yl]-phenyl}-amide ;
- 20 4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid (4-(4-(3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzyl)-piperazine-1-yl)-phenyl)-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid (4-{4-[3-(5-trifluoromethyl-[1,2,4]oxadiazol-3-yl)-benzyl]-piperazin-1-yl}-phenyl)-amide ;
- (4-{4-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazin-1-yl)-acetic acid ;
- 25 4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-[(biphenyl-3-ylmethyl)-carbamoyl]-methyl)-piperazin-1-yl)-phenyl]-amide ;
- 3-(4-{4-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperazin-1-ylmethyl)-benzoic acid ;
- 30 4'-Trifluoromethyl-biphenyl-2-carboxylic acid (4-{4-[3-(2,2,2-trifluoroethylcarbamoyl)-benzyl]-piperazin-1-yl}-phenyl)-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzoyl)-piperazin-1-yl]-phenyl]-amide ;
- 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-acetyl-piperazin-1-yl)-phenyl]-amide ;
- 35

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzenesulfonyl)-piperazin-1-yl]-phenyl]-amide ;

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-methanesulfonyl-piperazin-1-yl)-phenyl]-amide ;

5 4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[1-(3-cyano-benzyl)-piperidin-4-yl]-phenyl]-amide ;

N-{4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl}-2-pyrrol-1-yl-benzamide ;

N-{4-[4-(3-Cyano-benzyl)-piperazin-1-yl]-phenyl}-2-pyridin-2-yl-benzamide ;

or a physiologically acceptable salt, solvate or derivative thereof.

10

22. A compound selected from the group consisting of:

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

15

4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

20

6-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-[4-(3-cyano-benzyl)-piperazin-1-yl]-phenyl]-amide ;

4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid (4-{3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzyl}-piperazin-1-yl)-phenyl)-amide ;

25

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide ;

4'-Isopropyl-6-methoxy-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide ;

4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid [4-(4-carbamoylmethyl-piperazin-1-yl)-phenyl]-amide ;

30

4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid (4-(4-(3-(3-methyl-[1,2,4]oxadiazol-5-yl)-benzyl)-piperazine-1-yl)-phenyl)-amide ;

4'-Trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide ;

35

4'-Isopropyl-5-methyl-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide ;

5-Methyl-4'-trifluoromethyl-biphenyl-2-carboxylic acid [4-(4-(1H-pyrrol-2-ylmethyl)-piperazin-1-yl)-phenyl]-amide ;
or a physiologically acceptable salt, solvate or derivative thereof.

5 23. A compound according to any one of Claims 1 to 22 for use in therapy.


24. A method for the treatment of a mammal, including man, of conditions resulting from elevated circulating levels of apoB-100 comprising administration of an effective amount of a compound according to any one of claims 1 to 22 or a
10 pharmaceutically acceptable derivative thereof.

25. The use of a compound according to any one of claims 1 to 22 or a physiologically acceptable salt or solvate thereof in the manufacture of a medicament for use in the treatment of conditions resulting from elevated
15 circulating levels of apoB-100.

26. A pharmaceutical composition comprising a compound according to any one of claims 1 to 22 or a pharmaceutically acceptable derivative thereof together with one or more pharmaceutically acceptable carriers.

20 27. A process for the preparation of a compound of formula (I) comprising:


(A) reacting a compound of formula (II) with a compound of formula R¹-Z-X-L




where L represents a suitable halide leaving group or, where X is an oxo group, L may additionally represent a hydroxy group; or

30 (B) reaction of compounds of formula (III) and compounds of formula (VII)

88




(III)



(VII)

where L is defined above; or


(C) where Y is -O-C₁₋₄alkylene-, by reaction of a compound of formula (VIII) with a compound of formula R²-C₁₋₄alkylene-L, where L is defined above,




(VIII)

; or

(D) where at least part of X represents an alkylene link to the piperidine or piperazine group, by reacting a compound of formula (II) with a compound of formula (IX)



(II)



(IX)

where X' represents X minus a terminal methylene group; or

(E) reacting a compound of formula (I) to give a different compound of formula (I) using standard reaction conditions.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 99/09320

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D295/155 C07D295/135 A61K31/445 A61K31/495 A61P3/06
A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 23593 A (PFIZER INC.) 4 June 1998 (1998-06-04) page 2, line 10 -page 11, line 10	1,25
A	WO 96 40640 A (PFIZER INC.) 19 December 1996 (1996-12-19) cited in the application page 1 -page 6, line 20	1,25
A	EP 0 533 267 A (GLAXO GROUP LIMITED) 24 March 1993 (1993-03-24) page 3 -page 4	1,25
A	US 4 022 900 A (IAN WILLIAM MATHISON) 10 May 1977 (1977-05-10) column 1 -column 2	1,25
	-/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

23 March 2000

Date of mailing of the international search report

03/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 851 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Kyriakakou, G

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/JP 99/09320

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GB 1 067 817 A (AMERICAN CYAMAMID CO) the whole document	1,25

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/09320

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 24
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 24 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC 99/09320

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9823593 A	04-06-1998	AU 716151 B	17-02-2000
		AU 4634797 A	22-06-1998
		CN 1238764 A	15-12-1999
		EP 0944602 A	29-09-1999
		HR 970642 A	31-10-1998
		NO 992525 A	26-05-1999
WO 9640640 A	19-12-1996	CA 2223574 A	19-12-1996
		HU 9601566 A	29-09-1997
		AU 3585399 A	16-09-1999
		AU 703493 B	25-03-1999
		AU 5478496 A	19-12-1996
		BG 62442 B	30-11-1999
		BG 100637 A	31-03-1997
		BR 9602628 A	08-09-1996
		CN 1141918 A	05-02-1997
		CZ 9601644 A	15-01-1997
		EP 0832069 A	01-04-1998
		FI 974440 A	27-01-1998
		HR 960270 A	31-12-1997
		LV 11615 A	20-12-1996
		LV 11615 B	20-04-1997
		NO 962385 A	09-12-1996
		NZ 286733 A	26-02-1998
		PL 314636 A	09-12-1996
		SG 44952 A	19-12-1997
		SI 9600183 A	30-04-1997
		SK 72696 A	05-11-1997
		TR 961058 A	21-12-1996
		US 5919795 A	06-07-1999
EP 533267 A	24-03-1993	AU 2452892 A	25-03-1993
		AU 2568792 A	27-04-1993
		CA 2078507 A	19-03-1993
		CN 1073430 A	23-06-1993
		CZ 9400611 A	16-11-1994
		WO 9306084 A	01-04-1993
		FI 941261 A	17-03-1994
		JP 6107637 A	19-04-1994
		MX 9205278 A	01-03-1993
		NO 940974 A	17-03-1994
		US 5358948 A	25-10-1994
		ZA 9207106 A	17-03-1994
US 4022900 A	10-05-1977	BE 763149 A	16-07-1971
		CH 550797 A	28-06-1974
		DE 2101691 A	16-03-1972
		FR 2106399 A	05-05-1972
		GB 1312205 A	04-04-1973
		JP 48024396 B	20-07-1973
GB 1067817 A		DE 1445457 A	02-01-1969
		FR 94701 E	24-10-1969

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
 - ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
 - ☐ FADED TEXT OR DRAWING
 - ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
 - ☐ SKEWED/SLANTED IMAGES
 - ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
 - ☐ GRAY SCALE DOCUMENTS
 - ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
-
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
 - ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.